<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Endocrinol Metab</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Endocrinol Metab</journal-id><journal-id journal-id-type="publisher-id">jcem</journal-id><journal-title-group><journal-title>The Journal of Clinical Endocrinology and Metabolism</journal-title></journal-title-group><issn pub-type="ppub">0021-972X</issn><issn pub-type="epub">1945-7197</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38567654</article-id><article-id pub-id-type="pmc">11403317</article-id>
<article-id pub-id-type="doi">10.1210/clinem/dgae210</article-id><article-id pub-id-type="publisher-id">dgae210</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00250</subject></subj-group></article-categories><title-group><article-title>
<italic toggle="yes">MC4R</italic> Variants Modulate &#x3B1;-MSH and Setmelanotide Induced Cellular Signaling at Multiple Levels</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-8398-4667</contrib-id><name><surname>Rodr&#xED;guez Rond&#xF3;n</surname><given-names>Alejandra V</given-names></name><aff>
<institution>Obesity Center CGG and Expertise Center Genetic Obesity, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Internal Medicine, Division of Endocrinology, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Welling</surname><given-names>Mila S</given-names></name><aff>
<institution>Obesity Center CGG and Expertise Center Genetic Obesity, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Internal Medicine, Division of Endocrinology, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Pediatrics, Division of Endocrinology, Erasmus MC-Sophia Children's Hospital, University Medical Center Rotterdam</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5352-9328</contrib-id><name><surname>van den Akker</surname><given-names>Erica L T</given-names></name><aff>
<institution>Obesity Center CGG and Expertise Center Genetic Obesity, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Pediatrics, Division of Endocrinology, Erasmus MC-Sophia Children's Hospital, University Medical Center Rotterdam</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>van Rossum</surname><given-names>Elisabeth F C</given-names></name><aff>
<institution>Obesity Center CGG and Expertise Center Genetic Obesity, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Internal Medicine, Division of Endocrinology, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Boon</surname><given-names>Elles M J</given-names></name><aff>
<institution>Department of Human Genetics, Amsterdam University Medical Center</institution>, <addr-line>1105 AZ Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>van Haelst</surname><given-names>Mieke M</given-names></name><aff>
<institution>Department of Human Genetics, Amsterdam University Medical Center</institution>, <addr-line>1105 AZ Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Delhanty</surname><given-names>Patric J D</given-names></name><aff>
<institution>Obesity Center CGG and Expertise Center Genetic Obesity, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Internal Medicine, Division of Endocrinology, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff><xref rid="FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7182-3571</contrib-id><name><surname>Visser</surname><given-names>Jenny A</given-names></name><aff>
<institution>Obesity Center CGG and Expertise Center Genetic Obesity, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Internal Medicine, Division of Endocrinology, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff><xref rid="FM1" ref-type="author-notes"/><xref rid="dgae210-cor1" ref-type="corresp"/><!--j.visser@erasmusmc.nl--></contrib></contrib-group><author-notes><corresp id="dgae210-cor1">
<bold>Correspondence:</bold> Jenny A. Visser, PhD, <institution>Department</institution> of Internal Medicine, Erasmus MC, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Email: <email>j.visser@erasmusmc.nl</email>.</corresp><fn id="FM1"><p>Patric J. D. Delhanty and Jenny A. Visser Joint last author.</p></fn></author-notes><pub-date pub-type="collection"><month>10</month><year>2024</year></pub-date><pub-date pub-type="epub" iso-8601-date="2024-04-03"><day>03</day><month>4</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>03</day><month>4</month><year>2024</year></pub-date><volume>109</volume><issue>10</issue><fpage>2452</fpage><lpage>2466</lpage><history><date date-type="received"><day>05</day><month>12</month><year>2023</year></date><date date-type="editorial-decision"><day>27</day><month>3</month><year>2024</year></date><date date-type="corrected-typeset"><day>15</day><month>4</month><year>2024</year></date></history><permissions><copyright-statement>&#xA9; The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="dgae210.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Context</title><p>The melanocortin-4 receptor (<italic toggle="yes">MC4R</italic>) plays an important role in body weight regulation. Pathogenic <italic toggle="yes">MC4R</italic> variants are the most common cause of monogenic obesity.</p></sec><sec id="s2"><title>Objective</title><p>We have identified 17 <italic toggle="yes">MC4R</italic> variants in adult and pediatric patients with obesity. Here we aimed to functionally characterize these variants by analyzing 4 different aspects of MC4R signaling. In addition, we aimed to analyze the effect of setmelanotide, a potent MC4R agonist, on these MC4R variants.</p></sec><sec id="s3"><title>Materials and Methods</title><p>Cell surface expression and &#x3B1;-melanocyte stimulating hormone (&#x3B1;-MSH)- or setmelanotide-induced cAMP response, &#x3B2;-arrestin-2 recruitment, and ERK activation were measured in cells expressing either wild type or variant MC4R.</p></sec><sec id="s4"><title>Results</title><p>We found a large heterogeneity in the function of these variants. We identified variants with a loss of response for all studied MC4R signaling, variants with no cAMP accumulation or ERK activation but normal &#x3B2;-arrestin-2 recruitment, and variants with normal cAMP accumulation and ERK activation but decreased &#x3B2;-arrestin-2 recruitment, indicating disrupted desensitization and signaling mechanisms. Setmelanotide displayed a greater potency and similar efficacy as &#x3B1;-MSH and induced significantly increased maximal cAMP responses of several variants compared to &#x3B1;-MSH. Despite the heterogeneity in functional response, there was no apparent difference in the obesity phenotype in our patients.</p></sec><sec id="s5"><title>Conclusion</title><p>We show that these obesity-associated <italic toggle="yes">MC4R</italic> variants affect MC4R signaling differently yet lead to a comparable clinical phenotype. Our results demonstrate the clinical importance of assessing the effect of <italic toggle="yes">MC4R</italic> variants on a range of molecular signaling mechanisms to determine their association with obesity, which may aid in improving personalized treatment.</p></sec></abstract><kwd-group><kwd>melanocortin-4 receptor</kwd><kwd>genetic variation</kwd><kwd>obesity</kwd><kwd>setmelanotide</kwd><kwd>&#x3B1;-MSH</kwd><kwd>G-protein-coupled receptors</kwd><kwd>&#x3B2;-arrestins</kwd></kwd-group><counts><page-count count="15"/></counts></article-meta></front>
  <body>
    <p>Obesity is a public health concern that is caused by an imbalance in energy homeostasis and is associated with multiple comorbidities, including type 2 diabetes, cardiovascular disease, various types of cancer, infertility, and depression (<xref rid="dgae210-B1" ref-type="bibr">1-3</xref>). The obesogenic environment and a sedentary lifestyle contribute largely to obesity. However, there is also a genetic component to the regulation of body weight. Based on multiple twin studies, the hereditability of body weight is estimated at 40% to 70% (<xref rid="dgae210-B4" ref-type="bibr">4</xref>, <xref rid="dgae210-B5" ref-type="bibr">5</xref>). The predisposition to obesity is mainly polygenic, but in a significant minority of patients with obesity it can be monogenic (<xref rid="dgae210-B2" ref-type="bibr">2</xref>, <xref rid="dgae210-B6" ref-type="bibr">6</xref>). Monogenic obesity results mainly from pathogenic variants in genes affecting the evolutionarily conserved leptin-melanocortin pathway, the appetite regulatory system in the hypothalamus (<xref rid="dgae210-B7" ref-type="bibr">7</xref>, <xref rid="dgae210-B8" ref-type="bibr">8</xref>). One of these genes is the melanocortin-4 receptor (<italic toggle="yes">MC4R</italic>), and pathogenic variants in <italic toggle="yes">MC4R</italic> are the most frequent cause of monogenic obesity (<xref rid="dgae210-B9" ref-type="bibr">9</xref>, <xref rid="dgae210-B10" ref-type="bibr">10</xref>).</p>
    <p>Loss of function (LoF) <italic toggle="yes">MC4R</italic> variants are the most common monogenic cause of obesity. Affected individuals present with early-onset obesity, hyperphagia, hyperinsulinemia, increased bone mineral density, and increased linear growth (<xref rid="dgae210-B4" ref-type="bibr">4</xref>, <xref rid="dgae210-B11" ref-type="bibr">11</xref>, <xref rid="dgae210-B12" ref-type="bibr">12</xref>). The prevalence of LoF <italic toggle="yes">MC4R</italic> variants ranges from 0.5% in adults with obesity to 5.8% in children with severe early-onset obesity (<xref rid="dgae210-B13" ref-type="bibr">13</xref>, <xref rid="dgae210-B14" ref-type="bibr">14</xref>). Moreover, the prevalence of heterozygous <italic toggle="yes">MC4R</italic> carriers in Europe with a body mass index (BMI) greater than 30&#x2005;kg/m<sup>2</sup> is 1% to 2.5% (<xref rid="dgae210-B14" ref-type="bibr">14</xref>, <xref rid="dgae210-B15" ref-type="bibr">15</xref>). Also in mice, homozygous deficiency of <italic toggle="yes">Mc4r</italic> results in severe obesity and hyperphagia, with heterozygous mice having an intermediate phenotype (<xref rid="dgae210-B16" ref-type="bibr">16</xref>). These findings indicate that MC4R is a major regulator of appetite and energy balance in the leptin-melanocortin pathway (<xref rid="dgae210-B17" ref-type="bibr">17</xref>, <xref rid="dgae210-B18" ref-type="bibr">18</xref>).</p>
    <p>
<italic toggle="yes">MC4R</italic> is expressed in neurons of the paraventricular nucleus of the hypothalamus and signals predominantly through the G&#x3B1;<sub>s</sub> protein/cAMP pathway in response to the ligand &#x3B1;-melanocyte stimulating hormone (&#x3B1;-MSH) (<xref rid="dgae210-B9" ref-type="bibr">9</xref>, <xref rid="dgae210-B10" ref-type="bibr">10</xref>). Its activation leads to a reduction in food intake and an increase in energy expenditure (<xref rid="dgae210-B9" ref-type="bibr">9</xref>, <xref rid="dgae210-B10" ref-type="bibr">10</xref>, <xref rid="dgae210-B19" ref-type="bibr">19</xref>, <xref rid="dgae210-B20" ref-type="bibr">20</xref>). &#x3B1;-MSH is produced locally by pro-opiomelanocortin (POMC) neurons, through processing of the POMC polypeptide precursor, in response to leptin (<xref rid="dgae210-B9" ref-type="bibr">9</xref>, <xref rid="dgae210-B10" ref-type="bibr">10</xref>, <xref rid="dgae210-B19" ref-type="bibr">19</xref>, <xref rid="dgae210-B20" ref-type="bibr">20</xref>).</p>
    <p>More than 200 <italic toggle="yes">MC4R</italic> variants have been identified and associated with obesity (<xref rid="dgae210-B21" ref-type="bibr">21</xref>). The majority of the identified <italic toggle="yes">MC4R</italic> variants follow an autosomal dominant (monoallelic) inheritance pattern, and the pathogenic variant receptors show a LoF in G&#x3B1;<sub>s</sub> signaling (<xref rid="dgae210-B22" ref-type="bibr">22</xref>, <xref rid="dgae210-B23" ref-type="bibr">23</xref>). Most of these variants cause misfolding of the protein, leading to retention and/or degradation of the receptor by the quality control system (endoplasmic reticulum or Golgi apparatus), preventing receptor trafficking to the cell surface (<xref rid="dgae210-B24" ref-type="bibr">24</xref>, <xref rid="dgae210-B25" ref-type="bibr">25</xref>). However, some obesity-associated MC4R variants signal normally via cAMP, which has raised the possibility that they perturb other uncharacterized signaling pathways linking MC4R to the regulation of food intake (<xref rid="dgae210-B26" ref-type="bibr">26</xref>).</p>
    <p>In addition to the G&#x3B1;<sub>s</sub>/cAMP pathway, MC4R has been shown to signal through &#x3B2;-arrestins (<xref rid="dgae210-B27" ref-type="bibr">27</xref>). Recruitment of &#x3B2;-arrestin to the activated receptor leads to desensitization and internalization of the receptor into the cytosol but also may modulate the activation of the ERK pathway (<xref rid="dgae210-B28" ref-type="bibr">28-30</xref>). Indeed, knocking down <italic toggle="yes">ARRB2</italic>, which encodes &#x3B2;-arrestin-2, increased ERK1/2 phosphorylation in a cell model. Moreover, knocking down <italic toggle="yes">GNAS</italic>, which encodes the G&#x3B1;<sub>s</sub> protein, resulted in a complete inhibition of ERK1/2 phosphorylation (<xref rid="dgae210-B30" ref-type="bibr">30</xref>). This data, among other studies, suggests that MC4R-induced ERK signaling, possibly through G&#x3B1;s, may also contribute to the regulation of food intake (<xref rid="dgae210-B30" ref-type="bibr">30-33</xref>).</p>
    <p>Given the important role of MC4R in energy metabolism, MC4R is considered a potential drug target for the treatment of genetic obesity (<xref rid="dgae210-B34" ref-type="bibr">34-36</xref>). Setmelanotide (also named RM-493, BIM-22493, IRC-022493, and brand name Imcivree) is a synthetic cyclic MC4R agonist approved by the Food and Drug Administration and European Medicines Agency and shown to be effective in reducing body weight in patients with obesity caused by bi-allelic pathogenic <italic toggle="yes">POMC, PCSK1</italic>, or <italic toggle="yes">LEPR</italic> variants (<xref rid="dgae210-B35" ref-type="bibr">35</xref>, <xref rid="dgae210-B36" ref-type="bibr">36</xref>), as well as in diet-induced animal models (<xref rid="dgae210-B35" ref-type="bibr">35</xref>). Setmelanotide has a high affinity and specificity for MC4R (<xref rid="dgae210-B35" ref-type="bibr">35-37</xref>). Interestingly, setmelanotide also induced weight loss in <italic toggle="yes">Mc4r</italic> heterozygous knockout mice upon high-fat diet, while homozygous knockout mice were nonresponsive. Although the effect of setmelanotide in the <italic toggle="yes">Mc4r</italic> heterozygous knockout mice was less compared to wild type (WT) mice (<xref rid="dgae210-B35" ref-type="bibr">35</xref>), it may suggest that patients with a pathogenic <italic toggle="yes">MC4R</italic> variant might benefit from treatment with setmelanotide. This may be particularly relevant since carriers of heterozygous LoF <italic toggle="yes">MC4R</italic> variants respond poorly to diet- and exercise-induced weight loss (<xref rid="dgae210-B35" ref-type="bibr">35</xref>). Although only a few studies have been performed, results suggest that indeed setmelanotide may potentiate weight loss in patients with heterozygous <italic toggle="yes">MC4R</italic> variants, albeit that patients with variants upstream of the MC4R pathway (eg, POMC) are more responsive (<xref rid="dgae210-B35" ref-type="bibr">35</xref>).</p>
    <p>Here we have functionally analyzed 17 <italic toggle="yes">MC4R</italic> variants (1 homozygous, 1 compound heterozygous, and 15 heterozygous), identified in patients with severe obesity attending our Obesity Center CGG at Erasmus MC, Rotterdam, the Netherlands. We sought to gain more insight into the impact of these obesity-associated variants on various aspects of MC4R signaling: cell surface expression; total receptor expression; and &#x3B1;-MSH-induced cAMP production, &#x3B2;-arrestin-2 recruitment, and ERK pathway activation. In addition, we studied whether these variants were responsive to setmelanotide and compared functional results with aspects of their clinical phenotype.</p>
    <sec sec-type="materials|methods" id="dgae210-s0">
      <title>Materials and Methods</title>
      <sec id="dgae210-s0.1">
        <title>Clinical Data</title>
        <sec id="dgae210-s0.1.1">
          <title>Patient cohort and sequencing analysis</title>
          <p>Patient sample collection and sequencing analysis were performed by the Genome Diagnostics section of the Department of Genetics, UMC Utrecht, the Netherlands, and by the Department of Human Genetics, Amsterdam UMC, the Netherlands (<xref rid="dgae210-B2" ref-type="bibr">2</xref>). DNA samples were analyzed through diagnostic next-generation sequencing for genetic obesity disorders (obesitome). Additional DNA diagnostics, including whole exome sequencing, single-nucleotide polymorphism array, and karyotyping, were performed due to additional clinical features, such as developmental delay, intellectual deficit, short stature, or autism [Supplementary Table S1 (<xref rid="dgae210-B38" ref-type="bibr">38</xref>)]. The study involving human participants was reviewed and approved by the Ethical Committee of the Erasmus MC, University Medical Centre, Rotterdam (pediatric study MEC-2012-257 and adult study MEC-2023-0029). Informed consent of all participants and/or caregivers was obtained, when needed, according to the approved protocol.</p>
          <p>The <italic toggle="yes">MC4R</italic> variants were identified using obesity gene panels whose content evolved during the course of this study (<xref rid="dgae210-B2" ref-type="bibr">2</xref>, <xref rid="dgae210-B39" ref-type="bibr">39</xref>). <italic toggle="yes">MC4R</italic> variants were classified based on assessment of the available evidence, in line with the guidelines of the American College of Medical Genetics and Genomics (ACMG) Laboratory Practice Committee Working Group (<xref rid="dgae210-B40" ref-type="bibr">40</xref>), integrated with our professional expertise and knowledge of the genes and disorders we routinely offer diagnostic service for. Variants were classified into 1 of the 5 following categories: pathogenic, likely pathogenic, unknown/uncertain significance, likely benign or benign.</p>
        </sec>
        <sec id="dgae210-s0.1.2">
          <title>Resting energy expenditure measurement</title>
          <p>Resting energy expenditure (REE) was measured after an overnight fast using indirect calorimetry with a metabolic cart (Quark RMR, COSMED, Italy, for children and Q-NRG, COSMED, Italy, for adults). The Schofield equations were used to calculate predicted REE in children &lt;18 years (<xref rid="dgae210-B41" ref-type="bibr">41</xref>, <xref rid="dgae210-B42" ref-type="bibr">42</xref>). The predicted REE for patients &#x2265;18 years was calculated using the 1984 Harris&#x2013;Benedict equations (<xref rid="dgae210-B43" ref-type="bibr">43</xref>, <xref rid="dgae210-B44" ref-type="bibr">44</xref>).</p>
        </sec>
        <sec id="dgae210-s0.1.3">
          <title>Body composition measurement</title>
          <p>In children, body composition was measured using air displacement plethysmography (BOD POD, COSMED, Italy). The Lohman density model was used to measure the two-compartment body composition (fat-free mass and fat mass) from body volume, according to the manufacturer's recommendation (<xref rid="dgae210-B45" ref-type="bibr">45</xref>). For adults, body composition was measured using bio-impedance analysis (InBody S10, the Netherlands).</p>
        </sec>
      </sec>
      <sec id="dgae210-s0.2">
        <title>Functional Analysis</title>
        <sec id="dgae210-s0.2.1">
          <title>Cell lines, transfection, cloning, and site-directed mutagenesis</title>
          <p>For all experiments, human embryonic kidney 293 (HEK293) cells (ECACC cat. no. 85120602, RRID: CVCL_0045, UK) were cultured in DMEM/F12 (GIBCO, USA) containing 2.5&#x2005;mM GlutaMAX, 10% fetal calf serum (FCS), 100 units/mL penicillin, and 100&#x2005;&#xB5;g/mL streptomycin (P/S) (all media reagents from Thermo Fisher Scientific, the Netherlands) at 37 &#xB0;C in humidified air containing 5% CO<sub>2</sub>.</p>
          <p>The pcDNA3.1(+)-MC4R expression plasmid, containing the WT human <italic toggle="yes">MC4R</italic> cDNA was obtained from the cDNA Resource Center (<ext-link xlink:href="http://www.cdna.org" ext-link-type="uri">www.cdna.org</ext-link>, USA). For the GloSensor cAMP assay, pcDNA3.1(+) expression plasmid containing WT or variant MC4R and the GloSensor 22F plasmid (Promega, USA) were used to measure cAMP accumulation. For the &#x3B2;-arrestin-2 recruitment assay, the cDNA of human ARRB2 (&#x3B2;-arrestin-2; SinoBiological Europe GmbH, Germany) was cloned into the pBiT2.1-N [TK/SmBiT] vector, generating an N-terminally tagged ARRB2, and the cDNA of human MC4R was cloned into pBiT1.1-C [TK/LgBiT] vector (Promega, USA), generating a C-terminally LgBiT-tagged MC4R. For cell surface expression, the <italic toggle="yes">MC4R</italic> cDNA was cloned into pBiT3.1-secN [CMV/HiBiT/Blast] adding an IL-6 secretory signal peptide and HiBiT to its N-terminus (Promega, USA). The variants were generated in all of these constructs by site-directed mutagenesis, using the QuikChange II XL kit (Agilent Technologies, USA) according to the manufacturer's protocols [primers are listed in Supplementary Table S2 (<xref rid="dgae210-B38" ref-type="bibr">38</xref>)]. Sanger sequencing was used to verify all constructs.</p>
          <p>Transfections were performed using FuGENE HD (Promega, USA) or Lipofectamine 3000 (Thermo Fisher, the Netherlands) in serum-free Opti-MEM medium (Thermo Fisher, the Netherlands) according to the manufacturer's protocol.</p>
        </sec>
        <sec id="dgae210-s0.2.2">
          <title>Measurement of cAMP levels</title>
          <p>HEK293 cells (1.3 &#xD7; 10<sup>6</sup>) were seeded into 25 cm<sup>2</sup> culture flasks (Greiner Bio-One, Austria) and transiently transfected with 0.2&#x2005;&#xB5;g of WT or variant <italic toggle="yes">MC4R</italic> expression plasmid and 2&#x2005;&#xB5;g of pGloSensor-22F cAMP plasmid. The next day, cells were reseeded into a clear-bottom 96-well plate (100&#x2005;&#xB5;L/well) (Greiner Bio-One). After 24&#x2005;hours, culture media was replaced by 50&#x2005;&#xB5;L of 2% GloSensor cAMP reagent (Promega, USA) in CO<sub>2</sub>-independent serum-free stimulation medium (GIBCO, USA) containing P/S and 0.1% BSA and incubated for 2&#x2005;hours at 37 &#xB0;C. Levels of cAMP were measured using the GloSensor cAMP assay (Promega, USA) according to the manufacturer's protocols. Baseline luminescence was measured for 10&#x2005;minutes using the Victor X4 plate reader. Next, cells were stimulated with &#x3B1;-MSH (Tocris, UK) or setmelanotide (MedChem Express, the Netherlands) at concentrations ranging from 10<sup>&#x2212;11</sup> to 10<sup>&#x2212;6</sup> M for 20&#x2005;minutes and luminescence was measured.</p>
          <p>Independent experiments were performed to compare the cAMP response of &#x3B1;-MSH and setmelanotide on WT MC4R, according to the protocol described previously, except that luminescence was measured using the CLARIOstar Plus reader (BMG LABTECH, Germany). The assessment of the WT MC4R cAMP response was performed separately from that of the MC4R variants, explaining the variation in median effective concentration (EC<sub>50</sub>).</p>
        </sec>
        <sec id="dgae210-s0.2.3">
          <title>Measurement of &#x3B2;-arrestin-2 recruitment</title>
          <p>The interaction between MC4R and &#x3B2;-arrestin-2 was measured using the Nano-Glo Live Cell Assay System (Promega, USA). Briefly, 40 000 cells/well were seeded in poly-D-lysine-coated (Sigma Aldrich, USA) clear-bottom white 96-well plates, transiently transfected with 50&#x2005;ng/well of each of the constructs using Lipofectamine 3000, and incubated overnight at 37 &#xB0;C in culture medium. The next day, the culture medium was replaced with a CO<sub>2</sub>-independent medium (with 0.5% FCS and P/S), and Nano-Glo Live Cell Substrate (Promega, USA) was added to the wells and cells were temperature equilibrated for 10&#x2005;minutes inside the Victor X4 plate reader (Perkin Elmer, USA) before baseline measurement. Next, cells were stimulated with &#x3B1;-MSH or setmelanotide at concentrations ranging from 10<sup>&#x2212;11</sup> to 10<sup>&#x2212;5</sup> M. Cells were incubated for 4&#x2005;minutes before the luminescent signal was measured.</p>
          <p>Separate experiments were performed to directly compare &#x3B1;-MSH and setmelanotide induced &#x3B2;-arrestin-2 recruitment by WT MC4R, according to the protocol described previously, except that luminescence was measured using the CLARIOstar Plus reader (BMG LABTECH, Germany). This may explain the difference in EC<sub>50</sub> from experiments in which the variants were evaluated.</p>
        </sec>
        <sec id="dgae210-s0.2.4">
          <title>Quantification of extracellular and total expression</title>
          <p>Cell surface expression and total expression of WT and variant MC4R were measured using the Nano-Glo HiBiT Extracellular Detection System and Nano-Glo HiBiT Lytic Detection System respectively (Promega, USA). In brief, 20 000 cells/well were seeded in poly-D-lysine-coated clear-bottom white 96-well plates. The next day, cells were transiently transfected with 0.25&#x2005;ng/well of the constructs. After 24&#x2005;hours of transfection, the culture media was substituted for a CO<sub>2</sub> independent medium (0.5% FCS and P/S), and 50&#x2005;&#xB5;L of the HiBiT Extracellular or Lytic reagent was added into the wells. Cells were incubated for 10&#x2005;minutes at room temperature and then luminescence was measured.</p>
        </sec>
        <sec id="dgae210-s0.2.5">
          <title>Measurement of ERK pathway activation</title>
          <p>To assess the impact of MC4R variants on ERK activation, a serum response element (SRE) luciferase reporter plasmid was used (pGL4.33[luc2/SRE/Hygro]; Promega, USA). HEK293 cells were seeded on poly-D-lysine-coated white clear-bottom 96-well plates (20 000 cells/well) and cotransfected with the SRE reporter plasmid (50&#x2005;ng/well), WT, or variant <italic toggle="yes">MC4R</italic> expression plasmid (50&#x2005;ng/well) and the pSV40-RL plasmid (10&#x2005;ng/well) (Promega, USA). After 24&#x2005;hours, cells were starved overnight in 50&#x2005;&#xB5;L/well CO<sub>2</sub>-independent medium (0.1% BSA and P/S), then stimulated with &#x3B1;-MSH or setmelanotide at concentrations ranging from 10<sup>&#x2212;11</sup> to 10<sup>&#x2212;5</sup> M for 5&#x2005;hours at 37 &#xB0;C and 5% CO<sub>2</sub>. The stimulation was terminated by removing the media from the wells and lysing the cells with 25&#x2005;&#xB5;L/well lysis buffer. Plates were placed on a shaker for 10&#x2005;minutes at room temperature before storage at &#x2212;20 &#xB0;C. Luciferase activity was measured using the Dual-Glo Luciferase Assay System (Promega, USA) in the CLARIOstar Plus reader (BMG LABTECH, Germany).</p>
          <p>Separate experiments were performed to compare &#x3B1;-MSH and setmelanotide induced ERK activation through WT MC4R, according to the protocol described previously. This may explain the difference in EC<sub>50</sub> from experiments in which the variants were evaluated.</p>
        </sec>
        <sec id="dgae210-s0.2.6">
          <title>Statistical analysis</title>
          <p>GraphPad Prism (version 9.0.0 for Windows; RRID: SCR_002798; CA, USA) was used to perform nonlinear curve fitting of the dose-response data, to calculate EC<sub>50</sub>, and for all statistical tests. Comparison between WT and variant MC4R were assessed statistically using unpaired two-tailed <italic toggle="yes">t</italic>-tests, and a <italic toggle="yes">P</italic>-value &lt;.05 was considered significant. Results are derived from 3 to 4 independent experiments using duplicate samples. Data for MC4R variants are expressed relative to WT MC4R (set at 100%).</p>
          <p>The variants were categorized into 4 groups based on their mean %Emax cAMP response to &#x3B1;-MSH relative to WT: complete LoF (cLoF, &lt;20% of WT), partial LoF (pLoF, 20-80% of WT), WT-like (80-120% of WT), and gain of function (GoF, &gt;120% of WT).</p>
        </sec>
      </sec>
    </sec>
    <sec sec-type="results" id="dgae210-s1">
      <title>Results</title>
      <sec id="dgae210-s1.1">
        <title>Clinical Phenotype of Patients With Variants in MC4R</title>
        <p>One homozygous, 1 compound heterozygous, and 15 heterozygous <italic toggle="yes">MC4R</italic> variants were identified upon screening using an obesity gene panel in unrelated adult and pediatric patients of the outpatient clinic Obesity Center CGG, Erasmus MC: D37V, <bold>K71N</bold>, V95I, <bold>I102N</bold>, I102T, <underline>F149YfsX9</underline>, T150I, <underline>W174X</underline>, <underline>I195T</underline>, <underline>M215R</underline>, V253I, V255A, <bold>F262L</bold>, N274S, <bold>C293Y</bold>, P299H, and <bold>C318Y</bold> (<xref rid="dgae210-F1" ref-type="fig">Fig. 1</xref> and <xref rid="dgae210-T1" ref-type="table">Table 1</xref>). Variants in bold are novel variants. Underlined variants have been identified previously but were not functionally characterized. The other variants were assessed in part previously for cAMP response, ligand binding, and/or cell surface expression. Nucleotide changes of these <italic toggle="yes">MC4R</italic> variants are listed in <xref rid="dgae210-T1" ref-type="table">Table 1</xref>. All variants were identified and assessed in silico for pathogenicity according to the ACMG guidelines (<xref rid="dgae210-B40" ref-type="bibr">40</xref>) and reported as variants of unknown significance, likely pathogenic, or pathogenic (<xref rid="dgae210-T2" ref-type="table">Table 2</xref>).</p>
        <fig position="float" id="dgae210-F1" fig-type="figure">
          <label>Figure 1.</label>
          <caption>
            <p>Schematic model of MC4R. The identified variants (n = 17) in patients with obesity are highlighted in black and labeled with the respective amino acid substitution, frameshift, or deletion. (Snake diagram from <ext-link xlink:href="https://gpcrdb.org/protein/mc4r_human/" ext-link-type="uri">https://gpcrdb.org/protein/mc4r_human/</ext-link>).</p>
            <p>Abbreviations: ECL, extracellular loop; ICL, intracellular loop; MC4R, melanocortin-4 receptor.</p>
          </caption>
          <graphic xlink:href="dgae210f1" position="float"/>
        </fig>
        <table-wrap position="float" id="dgae210-T1">
          <label>Table 1.</label>
          <caption>
            <p>Clinical phenotype of patients with MC4R variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="2" colspan="1">Amino acid change</th>
                <th align="left" rowspan="2" colspan="1">Nucleotide change</th>
                <th align="left" rowspan="2" colspan="1">Sex</th>
                <th align="left" colspan="2" rowspan="1">Variant carried by parent</th>
                <th align="left" rowspan="2" colspan="1">Zygosity</th>
                <th align="left" rowspan="2" colspan="1">AoO obesity (years)</th>
                <th align="left" rowspan="2" colspan="1">Height (cm)</th>
                <th align="left" rowspan="2" colspan="1">Height (SDS)</th>
                <th align="left" rowspan="2" colspan="1">Weight (kg)</th>
                <th align="left" rowspan="2" colspan="1">Weight (SDS)</th>
                <th align="left" rowspan="2" colspan="1">BMI (kg/m<sup>2</sup>)</th>
                <th align="left" rowspan="2" colspan="1">BMI (SDS)</th>
                <th align="left" colspan="2" rowspan="1">Hyperphagia</th>
                <th align="left" rowspan="2" colspan="1">REE, kcal/day (% of reference)<italic toggle="yes"><sup><xref rid="tblfn2" ref-type="table-fn">a</xref></sup></italic></th>
                <th align="left" rowspan="2" colspan="1">Fat mass (%)<italic toggle="yes"><sup><xref rid="tblfn2a" ref-type="table-fn">b</xref>,<xref rid="tblfn3" ref-type="table-fn">c</xref></sup></italic></th>
              </tr>
              <tr>
                <th align="left" rowspan="1" colspan="1">Fa</th>
                <th align="left" rowspan="1" colspan="1">Mo</th>
                <th align="left" rowspan="1" colspan="1">Impaired satiety</th>
                <th align="left" rowspan="1" colspan="1">Impaired satiation</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td colspan="4" rowspan="1">
<bold>Pediatric patients (n = 11)</bold>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;K71N</td>
                <td rowspan="1" colspan="1">213G &gt; T</td>
                <td rowspan="1" colspan="1">F</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Homozygous</td>
                <td rowspan="1" colspan="1">3.0</td>
                <td rowspan="1" colspan="1">147.5</td>
                <td rowspan="1" colspan="1">0.9</td>
                <td rowspan="1" colspan="1">55.5</td>
                <td rowspan="1" colspan="1">3.3</td>
                <td rowspan="1" colspan="1">25.5</td>
                <td rowspan="1" colspan="1">3.5</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">102.0</td>
                <td rowspan="1" colspan="1">50.3</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;I102T</td>
                <td rowspan="1" colspan="1">305T &gt; C</td>
                <td rowspan="1" colspan="1">M</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Heterozygous</td>
                <td rowspan="1" colspan="1">0.5</td>
                <td rowspan="1" colspan="1">136.6</td>
                <td rowspan="1" colspan="1">1.4</td>
                <td rowspan="1" colspan="1">52.5</td>
                <td rowspan="1" colspan="1">4.8</td>
                <td rowspan="1" colspan="1">28.1</td>
                <td rowspan="1" colspan="1">5.1</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">95.0</td>
                <td rowspan="1" colspan="1">39.0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;T150I</td>
                <td rowspan="1" colspan="1">449C &gt; T</td>
                <td rowspan="1" colspan="1">M</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Heterozygous</td>
                <td rowspan="1" colspan="1">0.3</td>
                <td rowspan="1" colspan="1">106.0</td>
                <td rowspan="1" colspan="1">1.2</td>
                <td rowspan="1" colspan="1">34.2</td>
                <td rowspan="1" colspan="1">6.9</td>
                <td rowspan="1" colspan="1">30.4</td>
                <td rowspan="1" colspan="1">7.2</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">n.d.</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;W174X</td>
                <td rowspan="1" colspan="1">521G &gt; A</td>
                <td rowspan="1" colspan="1">M</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Heterozygous</td>
                <td rowspan="1" colspan="1">4.0</td>
                <td rowspan="1" colspan="1">114.8</td>
                <td rowspan="1" colspan="1">&#x2212;0.6</td>
                <td rowspan="1" colspan="1">29.7</td>
                <td rowspan="1" colspan="1">2.9</td>
                <td rowspan="1" colspan="1">22.5</td>
                <td rowspan="1" colspan="1">4.3</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">111.3</td>
                <td rowspan="1" colspan="1">38.6</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;I195T</td>
                <td rowspan="1" colspan="1">584T &gt; C</td>
                <td rowspan="1" colspan="1">F</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Heterozygous</td>
                <td rowspan="1" colspan="1">4.0</td>
                <td rowspan="1" colspan="1">144.2</td>
                <td rowspan="1" colspan="1">&#x2212;1.8</td>
                <td rowspan="1" colspan="1">67.7</td>
                <td rowspan="1" colspan="1">2.4</td>
                <td rowspan="1" colspan="1">32.6</td>
                <td rowspan="1" colspan="1">3.5</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">99.8</td>
                <td rowspan="1" colspan="1">33.9</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;M215R</td>
                <td rowspan="1" colspan="1">644T &gt; G</td>
                <td rowspan="1" colspan="1">M</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">Heterozygous</td>
                <td rowspan="1" colspan="1">3.0</td>
                <td rowspan="1" colspan="1">55.5</td>
                <td rowspan="1" colspan="1">3.3</td>
                <td rowspan="1" colspan="1">147.5</td>
                <td rowspan="1" colspan="1">0.9</td>
                <td rowspan="1" colspan="1">25.5</td>
                <td rowspan="1" colspan="1">3.5</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">98.8</td>
                <td rowspan="1" colspan="1">35.5</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;V255A</td>
                <td rowspan="1" colspan="1">764T &gt; C</td>
                <td rowspan="1" colspan="1">F</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Heterozygous</td>
                <td rowspan="1" colspan="1">5.0</td>
                <td rowspan="1" colspan="1">139.4</td>
                <td rowspan="1" colspan="1">0.8</td>
                <td rowspan="1" colspan="1">56.6</td>
                <td rowspan="1" colspan="1">3.6</td>
                <td rowspan="1" colspan="1">29.1</td>
                <td rowspan="1" colspan="1">3.8</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">93.3</td>
                <td rowspan="1" colspan="1">47.6</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;F262L</td>
                <td rowspan="1" colspan="1">784T &gt; C</td>
                <td rowspan="1" colspan="1">M</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">Heterozygous</td>
                <td rowspan="1" colspan="1">3.0</td>
                <td rowspan="1" colspan="1">174.5</td>
                <td rowspan="1" colspan="1">&#x2212;0.7</td>
                <td rowspan="1" colspan="1">121.6</td>
                <td rowspan="1" colspan="1">5.0</td>
                <td rowspan="1" colspan="1">39.9</td>
                <td rowspan="1" colspan="1">4.1</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">85.0</td>
                <td rowspan="1" colspan="1">42.3</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;N274S</td>
                <td rowspan="1" colspan="1">821A &gt; G</td>
                <td rowspan="1" colspan="1">M</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Heterozygous</td>
                <td rowspan="1" colspan="1">2.8</td>
                <td rowspan="1" colspan="1">174.6</td>
                <td rowspan="1" colspan="1">1.7</td>
                <td rowspan="1" colspan="1">117.0</td>
                <td rowspan="1" colspan="1">4.5</td>
                <td rowspan="1" colspan="1">38.4</td>
                <td rowspan="1" colspan="1">4.2</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">n.d.</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;C293Y</td>
                <td rowspan="1" colspan="1">878G &gt; A</td>
                <td rowspan="1" colspan="1">M</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Heterozygous</td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">176.3</td>
                <td rowspan="1" colspan="1">2.4</td>
                <td rowspan="1" colspan="1">85.3</td>
                <td rowspan="1" colspan="1">3.6</td>
                <td rowspan="1" colspan="1">27.4</td>
                <td rowspan="1" colspan="1">3.1</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">117.0</td>
                <td rowspan="1" colspan="1">n.d.</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;P299H</td>
                <td rowspan="1" colspan="1">896C &gt; A</td>
                <td rowspan="1" colspan="1">M</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Heterozygous</td>
                <td rowspan="1" colspan="1">3.3</td>
                <td rowspan="1" colspan="1">127.6</td>
                <td rowspan="1" colspan="1">0.8</td>
                <td rowspan="1" colspan="1">54.0</td>
                <td rowspan="1" colspan="1">5.7</td>
                <td rowspan="1" colspan="1">33.2</td>
                <td rowspan="1" colspan="1">6.6</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">89.0</td>
                <td rowspan="1" colspan="1">48.4</td>
              </tr>
              <tr>
                <td colspan="17" rowspan="1">
<bold>Adult patients (n = 6)</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;D37V</td>
                <td rowspan="1" colspan="1">110A &gt; T</td>
                <td rowspan="1" colspan="1">F</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">Compound heterozygous<italic toggle="yes"><sup><xref rid="tblfn4" ref-type="table-fn">d</xref></sup></italic></td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">168.5</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">167.0</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">58.8</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">104.2</td>
                <td rowspan="1" colspan="1">57.8</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;V95I</td>
                <td rowspan="1" colspan="1">283G &gt; T</td>
                <td rowspan="1" colspan="1">F</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Heterozygous</td>
                <td rowspan="1" colspan="1">6.0</td>
                <td rowspan="1" colspan="1">144.2</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">74.9</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">36.0</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">88.0</td>
                <td rowspan="1" colspan="1">n.d.</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;I102N</td>
                <td rowspan="1" colspan="1">305T &gt; A</td>
                <td rowspan="1" colspan="1">F</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Heterozygous</td>
                <td rowspan="1" colspan="1">6.0</td>
                <td rowspan="1" colspan="1">180.0</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">182.2</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">56.2</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">57.9</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;F149YfsX9</td>
                <td rowspan="1" colspan="1">446-450del</td>
                <td rowspan="1" colspan="1">F</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Heterozygous</td>
                <td rowspan="1" colspan="1">4.0</td>
                <td rowspan="1" colspan="1">166.1</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">153.4</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">55.6</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">82.0</td>
                <td rowspan="1" colspan="1">55.3</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;V253I</td>
                <td rowspan="1" colspan="1">757G &gt; A</td>
                <td rowspan="1" colspan="1">M</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Heterozygous</td>
                <td rowspan="1" colspan="1">0.0</td>
                <td rowspan="1" colspan="1">191.7</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">141.7</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">38.6</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">94.6</td>
                <td rowspan="1" colspan="1">41.0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;C318Y</td>
                <td rowspan="1" colspan="1">953G &gt; A</td>
                <td rowspan="1" colspan="1">F</td>
                <td rowspan="1" colspan="1">No</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">Heterozygous</td>
                <td rowspan="1" colspan="1">0.3</td>
                <td rowspan="1" colspan="1">164.1</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">113.3</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">42.1</td>
                <td rowspan="1" colspan="1">n.d.</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">118.0</td>
                <td rowspan="1" colspan="1">48.5</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="tblfn1">
              <p>Abbreviations: AoO, age of onset; BMI, body mass index; F, female; Fa, father; M, male; MC4R, melanocortin-4 receptor; Mo, mother; n.d, not determined; REE, resting energy expenditure.</p>
            </fn>
            <fn id="tblfn2">
              <p>
<sup>
<italic toggle="yes">a</italic>
</sup>Measured by indirect calorimetry, reference values were calculated using the Schofield formula for children or Harris&#x2013;Benedict formula for adults.</p>
            </fn>
            <fn id="tblfn2a">
              <p>
<sup>
<italic toggle="yes">b</italic>
</sup>Measured with bioelectrical impedance analysis.</p>
            </fn>
            <fn id="tblfn3">
              <p>
<sup>
<italic toggle="yes">c</italic>
</sup>Measured with BODPOD.</p>
            </fn>
            <fn id="tblfn4">
              <p>
<sup>
<italic toggle="yes">d</italic>
</sup>Patient also carries the pathogenic variant Y35X.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <table-wrap position="float" id="dgae210-T2">
          <label>Table 2.</label>
          <caption>
            <p>MC4R variants: in silico predicted pathogenicity and functional outcome</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">Amino acid change</th>
                <th align="left" rowspan="1" colspan="1">Nucleotide change</th>
                <th align="left" rowspan="1" colspan="1">Predicted<italic toggle="yes"><sup><xref rid="tblfn6" ref-type="table-fn">a</xref></sup></italic></th>
                <th align="left" rowspan="1" colspan="1">&#x3B1;-MSH induced cAMP response</th>
                <th align="left" rowspan="1" colspan="1">Classification<italic toggle="yes"><sup><xref rid="tblfn7" ref-type="table-fn">b</xref></sup></italic></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">D37V<italic toggle="yes"><sup><xref rid="tblfn8" ref-type="table-fn">c</xref></sup></italic></td>
                <td rowspan="1" colspan="1">110A &gt; T</td>
                <td rowspan="1" colspan="1">P</td>
                <td rowspan="1" colspan="1">pLoF</td>
                <td rowspan="1" colspan="1">III/IV</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">K71N</td>
                <td rowspan="1" colspan="1">213G &gt; T</td>
                <td rowspan="1" colspan="1">US</td>
                <td rowspan="1" colspan="1">pLoF</td>
                <td rowspan="1" colspan="1">I/II</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">V95I</td>
                <td rowspan="1" colspan="1">283G &gt; T</td>
                <td rowspan="1" colspan="1">P</td>
                <td rowspan="1" colspan="1">pLoF</td>
                <td rowspan="1" colspan="1">III/IV</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">I102T</td>
                <td rowspan="1" colspan="1">305T &gt; C</td>
                <td rowspan="1" colspan="1">US</td>
                <td rowspan="1" colspan="1">cLoF</td>
                <td rowspan="1" colspan="1">I/II</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">I102N</td>
                <td rowspan="1" colspan="1">305T &gt; A</td>
                <td rowspan="1" colspan="1">LP</td>
                <td rowspan="1" colspan="1">cLoF</td>
                <td rowspan="1" colspan="1">III/IV</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">F149YfsX9</td>
                <td rowspan="1" colspan="1">446-450del</td>
                <td rowspan="1" colspan="1">LP</td>
                <td rowspan="1" colspan="1">cLoF</td>
                <td rowspan="1" colspan="1">I</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">T150I</td>
                <td rowspan="1" colspan="1">449C &gt; T</td>
                <td rowspan="1" colspan="1">LP</td>
                <td rowspan="1" colspan="1">cLoF</td>
                <td rowspan="1" colspan="1">II</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">W174X</td>
                <td rowspan="1" colspan="1">521G &gt; A</td>
                <td rowspan="1" colspan="1">LP</td>
                <td rowspan="1" colspan="1">cLoF</td>
                <td rowspan="1" colspan="1">I</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">I195T</td>
                <td rowspan="1" colspan="1">584T &gt; C</td>
                <td rowspan="1" colspan="1">US</td>
                <td rowspan="1" colspan="1">WT-like</td>
                <td rowspan="1" colspan="1">II/V</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">M215R</td>
                <td rowspan="1" colspan="1">644T &gt; G</td>
                <td rowspan="1" colspan="1">US</td>
                <td rowspan="1" colspan="1">cLoF</td>
                <td rowspan="1" colspan="1">I</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">V253I</td>
                <td rowspan="1" colspan="1">757G &gt; A</td>
                <td rowspan="1" colspan="1">US</td>
                <td rowspan="1" colspan="1">pLoF</td>
                <td rowspan="1" colspan="1">III/IV</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">V255A</td>
                <td rowspan="1" colspan="1">764T &gt; C</td>
                <td rowspan="1" colspan="1">US</td>
                <td rowspan="1" colspan="1">WT-like</td>
                <td rowspan="1" colspan="1">V</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">F262L</td>
                <td rowspan="1" colspan="1">784T &gt; C</td>
                <td rowspan="1" colspan="1">US</td>
                <td rowspan="1" colspan="1">pLoF</td>
                <td rowspan="1" colspan="1">III/IV</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">N274S</td>
                <td rowspan="1" colspan="1">821A &gt; G</td>
                <td rowspan="1" colspan="1">US</td>
                <td rowspan="1" colspan="1">WT-like</td>
                <td rowspan="1" colspan="1">V</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">C293Y</td>
                <td rowspan="1" colspan="1">878G &gt; A</td>
                <td rowspan="1" colspan="1">US</td>
                <td rowspan="1" colspan="1">cLoF</td>
                <td rowspan="1" colspan="1">I/II</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">P299H</td>
                <td rowspan="1" colspan="1">896C &gt; A</td>
                <td rowspan="1" colspan="1">LP</td>
                <td rowspan="1" colspan="1">cLoF</td>
                <td rowspan="1" colspan="1">I</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">C318Y</td>
                <td rowspan="1" colspan="1">953G &gt; A</td>
                <td rowspan="1" colspan="1">US</td>
                <td rowspan="1" colspan="1">GoF</td>
                <td rowspan="1" colspan="1">&#x2014;</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="tblfn5">
              <p>Abbreviations: cLoF, complete loss-of-function; GoF, gain-of-function; MC4R, melanocortin-4 receptor; n.d., not determined; pLoF, partial loss-of-function; WT-like, wildtype-like.</p>
            </fn>
            <fn id="tblfn6">
              <p>
<sup>
<italic toggle="yes">a</italic>
</sup>Variants were classified into 5 categories: pathogenic (P), likely pathogenic (LP), unknown/uncertain significance (US), likely benign (LB), or benign (B).</p>
            </fn>
            <fn id="tblfn7">
              <p>
<sup>
<italic toggle="yes">b</italic>
</sup>Molecular classification of the MC4R variants identified in patients according to Tao (<xref rid="dgae210-B56" ref-type="bibr">56</xref>). class: (I) null mutations, (II) intracellularly trapped variants, (III) binding defective variants, (IV) signaling defective variants, and (V) variants with apparently normal function.</p>
            </fn>
            <fn id="tblfn8">
              <p>
<sup>
<italic toggle="yes">c</italic>
</sup>Patient also carries the pathogenic variant Y35X.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>The detected variants were scattered throughout the MC4R protein but were located mostly in the transmembrane domains (<xref rid="dgae210-F1" ref-type="fig">Fig. 1A</xref>). Of these variants, 10 heterozygous variants and 1 homozygous variant were found in pediatric patients with severe obesity (<xref rid="dgae210-T1" ref-type="table">Table 1</xref>). The median BMI- SD score (SDS), which adjusts for age and sex of these patients, was +4.2 SDS (ranging from +3 +7 SDS), indicating severe obesity. Their median age of obesity onset was 3 years, indicating early onset (&lt;5 years). Six heterozygous variants were identified in adult patients (<xref rid="dgae210-T1" ref-type="table">Table 1</xref>). The median BMI of these patients was 48.8&#x2005;kg/m<sup>2</sup> (ranging from 36 to 58.8&#x2005;kg/m<sup>2</sup>), and median age of obesity onset was 2.5 years. Of all patients, 12 (6 pediatric and 6 adult) presented with hyperphagia (<xref rid="dgae210-T1" ref-type="table">Table 1</xref>), and 13 patients (9 pediatric and 4 adults) had obesity-related comorbidities [Supplementary Table S3 and S4 (<xref rid="dgae210-B38" ref-type="bibr">38</xref>)]. Of these 13 patients, 10 patients were hyperinsulinemic and 7 were dyslipidemic. REE and fat mass are described in <xref rid="dgae210-T1" ref-type="table">Table 1</xref>.</p>
      </sec>
      <sec id="dgae210-s1.2">
        <title>Functional Analysis</title>
        <sec id="dgae210-s1.2.1">
          <title>Setmelanotide has similar efficacy but greater potency than &#x3B1;-MSH in stimulating the MC4R signaling pathways</title>
          <p>We determined the efficacy and potency of &#x3B1;-MSH and setmelanotide by assessing the WT MC4R canonical G&#x3B1;<sub>s</sub>-dependent cAMP response, &#x3B2;-arrestin-2 recruitment, and ERK activation (<xref rid="dgae210-F2" ref-type="fig">Fig. 2A&#x2013;2C</xref>). The efficacy of setmelanotide in eliciting a signaling response at MC4R was similar to that of &#x3B1;-MSH (<italic toggle="yes">P</italic> &gt; .05; <xref rid="dgae210-F2" ref-type="fig">Fig. 2A&#x2013;2C</xref>). However, as reported previously (<xref rid="dgae210-B35" ref-type="bibr">35</xref>, <xref rid="dgae210-B46" ref-type="bibr">46</xref>), setmelanotide had a significantly 22-fold greater potency than &#x3B1;-MSH for cAMP response (EC<sub>50</sub>: 0.2&#x2005;nM vs 11.9&#x2005;nM, respectively) (<xref rid="dgae210-F2" ref-type="fig">Fig. 2A</xref>). Setmelanotide also had a significantly 21-fold and 40-fold greater potency for &#x3B2;-arrestin-2 recruitment and ERK activation, respectively, compare to &#x3B1;-MSH (<xref rid="dgae210-F2" ref-type="fig">Fig. 2B</xref> and <xref rid="dgae210-F2" ref-type="fig">2C</xref>).</p>
          <fig position="float" id="dgae210-F2" fig-type="figure">
            <label>Figure 2.</label>
            <caption>
              <p>Setmelanotide has a greater potency but similar efficacy as &#x3B1;-MSH. Effect of &#x3B1;-MSH and setmelanotide on efficacy (Emax) and potency (EC<sub>50</sub>) of MC4R cAMP response (A), &#x3B2;-arrestin-2 recruitment (B), and ERK activation (C). The cAMP response is presented as Emax relative to WT MC4R upon &#x3B1;-MSH stimulation. Values represent mean &#xB1; SEM from 3 to 4 independent experiments performed in duplicate. Statistical analysis was performed using unpaired two-tailed <italic toggle="yes">t</italic>-test; confidence level = 95%; <sup>*</sup><italic toggle="yes">P</italic> &#x2264; .05 and **<italic toggle="yes">P</italic> &#x2264; .001.</p>
              <p>Abbreviations: &#x3B1;-MSH, &#x3B1;-melanocyte stimulating hormone; EC<sub>50,</sub> median effective concentration; Emax, maximum effect; MC4R, melanocortin-4 receptor; WT, wild type.</p>
            </caption>
            <graphic xlink:href="dgae210f2" position="float"/>
          </fig>
        </sec>
        <sec id="dgae210-s1.2.2">
          <title>MC4R variants affect ligand-induced cAMP response</title>
          <p>To determine the impact of MC4R variants on receptor signaling, we next performed independent experiments to assess the canonical G&#x3B1;<sub>s</sub>-dependent cAMP response upon ligand stimulation [<xref rid="dgae210-F3" ref-type="fig">Fig. 3A&#x2013;3D</xref> and Supplementary Table S5 (<xref rid="dgae210-B38" ref-type="bibr">38</xref>)]. Eight of the 17 variants (I102N, I102T, F149YfsX9, T150I, W174X, M215R, C293Y, and P299H) showed an &#x3B1;-MSH-induced cAMP response that was less than 20% of WT (<italic toggle="yes">P</italic> &lt; .001) and were therefore classified as cLoF variants (<xref rid="dgae210-F3" ref-type="fig">Fig. 3A</xref>). Five variants (D37V, K71N, V95I, V253I, and F262L) showed a partial cAMP responses to &#x3B1;-MSH stimulation with an Emax between 20% and 80% of WT (all <italic toggle="yes">P</italic> &lt; .001) and were classified as pLoF variants (<xref rid="dgae210-F3" ref-type="fig">Fig. 3B</xref>). Variants I195T, V255A, and N274S showed normal &#x3B1;-MSH-induced cAMP responses, with a mean Emax similar to WT (all <italic toggle="yes">P</italic> &gt; .05) (<xref rid="dgae210-F3" ref-type="fig">Fig. 3C</xref>). Lastly, C318Y displayed an increased cAMP response (&gt;120% of WT, <italic toggle="yes">P</italic> &lt; .01) and was classified as a GoF variant (<xref rid="dgae210-F3" ref-type="fig">Fig. 3D</xref>). Based on their &#x3B1;-MSH-induced cAMP response, we classified these variants as cLoF, pLoF, WT-like, or GoF variants.</p>
          <fig position="float" id="dgae210-F3" fig-type="figure">
            <label>Figure 3.</label>
            <caption>
              <p>Ligand-induced cAMP response in HEK293 cells transfected with the MC4R variants. Dose-response curves for &#x3B1;-MSH (A-D) and setmelanotide (E-H) were generated. The cAMP response is expressed as Emax relative to WT MC4R (%WT). Emax (%WT) was compared between &#x3B1;-MSH and setmelanotide (I). The relative potency of setmelanotide is expressed as the EC<sub>50</sub> ratio of setmelanotide and &#x3B1;-MSH. For cLoF MC4R variants the EC<sub>50</sub> could be calculated; therefore the relative potency is expressed as n.d. (J). Values represent mean &#xB1; SEM from 3 to 4 independent experiments performed in duplicate. Statistical analysis was performed using unpaired two-tailed <italic toggle="yes">t</italic>-test; confidence level = 95%; <sup>*</sup><italic toggle="yes">P</italic> &#x2264; .05 and **<italic toggle="yes">P</italic> &#x2264; .001.</p>
              <p>Abbreviations: &#x3B1;-MSH, &#x3B1;-melanocyte stimulating hormone; cLoF, complete loss of function; EC<sub>50,</sub> median effective concentration; Emax, maximum effect; HEK293, human embryonic kidney 293; MC4R, melanocortin-4 receptor; n.d., not determined; WT, wild type.</p>
            </caption>
            <graphic xlink:href="dgae210f3" position="float"/>
          </fig>
          <p>We also investigated the effects of setmelanotide on the cAMP response of these variants [<xref rid="dgae210-F3" ref-type="fig">Fig. 3E&#x2013;3H</xref> and Supplementary Table S5 (<xref rid="dgae210-B38" ref-type="bibr">38</xref>)]. Comparing the %WT Emax in response to &#x3B1;-MSH and setmelanotide (<xref rid="dgae210-F3" ref-type="fig">Fig. 3I</xref>) showed that setmelanotide increased the %WT Emax of 3 variants (I102N, I102T, and N274S) compared to &#x3B1;-MSH. For I102T, the mean Emax increased significantly from 21.3% &#xB1; 4.3 to 56% &#xB1; 3.7 (<italic toggle="yes">P</italic> &lt; .05), changing it from a cLoF to a pLoF variant. Upon stimulation with setmelanotide, N274S behaved as a GoF variant; however, the mean %WT Emax (126% &#xB1; 8.5 of WT) was not significantly different from that upon stimulation with &#x3B1;-MSH (101% &#xB1; 8.9) (<italic toggle="yes">P</italic> &gt; .05). Interestingly, for variant K71N, stimulation with setmelanotide resulted in a significantly lower %WT Emax relative to WT compared to &#x3B1;-MSH (58% &#xB1; 3.7 vs 36% &#xB1; 2.4, respectively, <italic toggle="yes">P</italic> &lt; .05).</p>
          <p>Furthermore, setmelanotide had a greater potency than &#x3B1;-MSH for several of the variants [Supplementary Table S4 (<xref rid="dgae210-B38" ref-type="bibr">38</xref>)]. Analyzing the EC<sub>50</sub> ratio for setmelanotide relative to &#x3B1;-MSH for those 10 MC4R variants that displayed pLoF to GoF in cAMP signaling in response to either &#x3B1;-MSH or setmelanotide showed that setmelanotide has a potency 2- to 15-fold greater than &#x3B1;-MSH (<xref rid="dgae210-F3" ref-type="fig">Fig. 3J</xref>).</p>
        </sec>
        <sec id="dgae210-s1.2.3">
          <title>MC4R variants have different effects on ligand-induced recruitment of &#x3B2;-arrestin-2</title>
          <p>To determine the impact of MC4R variants on ligand-induced recruitment of &#x3B2;-arrestin-2, we investigated the interaction between MC4R and &#x3B2;-arrestin-2 using the NanoBiT protein interaction assay [<xref rid="dgae210-F4" ref-type="fig">Fig. 4</xref> and Supplementary Table S6 (<xref rid="dgae210-B38" ref-type="bibr">38</xref>)]. First, we measured the recruitment of &#x3B2;-arrestin-2 to MC4R variants in response to &#x3B1;-MSH (<xref rid="dgae210-F4" ref-type="fig">Fig. 4A&#x2013;4D</xref>). Most cLoF variants (I102N, F149YfsX9, T150I, W174X, M215R, C293Y, and P299H) had lost their ability to recruit &#x3B2;-arrestin-2 (<italic toggle="yes">P</italic> &lt; .0001) in response to &#x3B1;-MSH (<xref rid="dgae210-F4" ref-type="fig">Fig. 4A</xref>). However, T150I showed WT-like levels of &#x3B1;-MSH-induced recruitment of &#x3B2;-arrestin-2 (<italic toggle="yes">P</italic> &gt; .05). Most pLoF variants (K71N, V95I, V253I, and F262L) also showed a partial response to recruit &#x3B2;-arrestin-2 (all <italic toggle="yes">P</italic> &gt; .05), although K71N displayed constitutive recruitment of &#x3B2;-arrestin-2 under basal conditions and was only partly responsive to ligand stimulation in the high micromolar range. D37V resulted in increased &#x3B2;-arrestin-2 recruitment (<italic toggle="yes">P</italic> &gt; .05) (<xref rid="dgae210-F4" ref-type="fig">Fig. 4B</xref>). Of the variants with a normal cAMP response, V255A also displayed normal &#x3B2;-arrestin-2 recruitment (<italic toggle="yes">P</italic> &gt; .05), while I195T and N274S yielded a partial loss of &#x3B2;-arrestin-2 recruitment (<italic toggle="yes">P</italic> &lt; .001) (<xref rid="dgae210-F4" ref-type="fig">Fig. 4C</xref>). In particular for I195T, &#x3B1;-MSH-induced &#x3B2;-arrestin-2 recruitment was significantly reduced to 36% &#xB1; 4.8. Lastly, C318Y, a GoF variant, displayed a complete loss in &#x3B2;-arrestin-2 recruitment (<italic toggle="yes">P</italic> &lt; .001) (<xref rid="dgae210-F4" ref-type="fig">Fig. 4D</xref>).</p>
          <fig position="float" id="dgae210-F4" fig-type="figure">
            <label>Figure 4.</label>
            <caption>
              <p>Ligand-induced &#x3B2;-arrestin-2 recruitment in HEK293 cells transfected with the MC4R variants. Dose-response curves for &#x3B1;-MSH (A-D) and setmelanotide (E-H) were generated. The &#x3B2;-arrestin-2 recruitment is expressed as Emax relative to WT MC4R (%WT). Emax (%WT) was compared between &#x3B1;-MSH and setmelanotide (I). The relative potency of setmelanotide is expressed as the EC<sub>50</sub> ratio of setmelanotide and &#x3B1;-MSH. For cLoF MC4R variants the EC<sub>50</sub> could be calculated; therefore the relative potency is expressed as n.d. (J). Values represent mean &#xB1; SEM from 3 to 4 independent experiments performed in duplicate. Statistical analysis was performed using unpaired two-tailed <italic toggle="yes">t</italic>-test; confidence level = 95%; <sup>*</sup><italic toggle="yes">P</italic> &#x2264; .05 and **<italic toggle="yes">P</italic> &#x2264; .001. Variants are ordered from cLoF, pLoF, WT-like, to GoF based on the &#x3B1;-MSH-induced cAMP response.</p>
              <p>Abbreviations: &#x3B1;-MSH, &#x3B1;-melanocyte stimulating hormone; cLoF, complete loss of function; EC<sub>50,</sub> median effective concentration; Emax, maximum effect; GoF, gain of function; HEK293, human embryonic kidney 293; MC4R, melanocortin-4 receptor; n.d., not determined; pLoF, partial loss of function; WT, wild type.</p>
            </caption>
            <graphic xlink:href="dgae210f4" position="float"/>
          </fig>
          <p>Second, analyzing the effect of setmelanotide on &#x3B2;-arrestin-2 recruitment by these MC4R variants, we found a pattern of effect of setmelanotide across the variants that was very similar to that of &#x3B1;-MSH [<xref rid="dgae210-F4" ref-type="fig">Fig. 4E&#x2013;4I</xref> and Supplementary Table S6 (<xref rid="dgae210-B38" ref-type="bibr">38</xref>)]. However, for 4 variants (D37V, I195T, F262L, and N274S), the potency of setmelanotide was increased 20- to 50-fold compared to 10-fold for the WT receptor, while for 4 other variants (K71N, V95I, I102N, and T150I) it was less potent in recruiting &#x3B2;-arrestin-2 (<xref rid="dgae210-F4" ref-type="fig">Fig. 4J</xref>). V255A resulted in significantly reduced efficacy but increased potency upon setmelanotide stimulation compared to &#x3B1;-MSH.</p>
        </sec>
        <sec id="dgae210-s1.2.4">
          <title>MC4R variants affect cell surface and total receptor expression</title>
          <p>Next, we measured the cell surface expression and total levels of expression of the MC4R variants [<xref rid="dgae210-F5" ref-type="fig">Fig. 5A</xref> and Supplementary Table S7 (<xref rid="dgae210-B38" ref-type="bibr">38</xref>), and 5B and Supplementary Table S8 (<xref rid="dgae210-B38" ref-type="bibr">38</xref>), respectively]. Five cLoF variants (W174X, F149YfsX9, M215R, C293Y, and P299H) were undetectable at the cell surface (<xref rid="dgae210-F5" ref-type="fig">Fig. 5A</xref>), and also had low to undetectable total levels of expression (all <italic toggle="yes">P</italic> &lt; .0001) (<xref rid="dgae210-F5" ref-type="fig">Fig. 5B</xref>). Two other cLoF variants (I102T and T150I) displayed reduced cell surface and total expression (<italic toggle="yes">P</italic> &lt; .01). For the pLoF variants, D37V and K71N showed reduced cell surface expression (<italic toggle="yes">P</italic> &lt; .001) combined with either normal (D37V) or reduced (K71N) total expression levels. I102N showed normal cell surface expression (<italic toggle="yes">P</italic> &gt; .05) but a lower total expression level (<italic toggle="yes">P</italic> &lt; .05). V95I, V253I, and F262L were expressed at the cell surface at significantly increased levels (<italic toggle="yes">P</italic> &lt; .05), combined with either significantly reduced level (<italic toggle="yes">P</italic> &lt; .05) (V253 and F262L) or normal (V95I) total expression levels. The WT-like variant I195T displayed significantly reduced cell surface expression (<italic toggle="yes">P</italic> &lt; .05) and reduced total expression levels (<italic toggle="yes">P</italic> &lt; .001). For the other WT-like variants, V255A and N274S, cell surface expression (<italic toggle="yes">P</italic> &gt; .05) and total expression levels were not affected (<italic toggle="yes">P</italic> &gt; .05). Also the GoF variant C318Y had a WT-like cell surface expression and total expression levels (<italic toggle="yes">P</italic> = .05).</p>
          <fig position="float" id="dgae210-F5" fig-type="figure">
            <label>Figure 5.</label>
            <caption>
              <p>Cell surface expression (A) and total expression (B) of MC4R variants in HEK293 cells. The expression of the WT MC4R is set at 100% and variants are expressed as %WT. Values represent mean &#xB1; SEM from 3 to 4 independent experiments performed in quadruplicate. individual experiments are indicated by points in bar charts (two-tailed <italic toggle="yes">t</italic>-test; 95% confidence level; <sup>*</sup><italic toggle="yes">P</italic> &#x2264; .05 and **<italic toggle="yes">P</italic> &#x2264; .001). Variants are ordered from cLoF, pLoF, WT-like, to GoF based on the &#x3B1;-MSH-induced cAMP response.</p>
              <p>Abbreviations: &#x3B1;-MSH, &#x3B1;-melanocyte stimulating hormone; cLoF, complete loss of function; GoF, gain of function; HEK293, human embryonic kidney 293; MC4R, melanocortin-4 receptor; pLoF, partial loss of function; WT, wild type.</p>
            </caption>
            <graphic xlink:href="dgae210f5" position="float"/>
          </fig>
        </sec>
        <sec id="dgae210-s1.2.5">
          <title>Cell surface-expressed MC4R variants affect ERK signaling</title>
          <p>We next quantified the impact of MC4R variants on ligand-induced ERK activation. For this analysis, using the SRE-luciferase reporter assay, we selected those MC4R variants that displayed cell surface expression [<xref rid="dgae210-F6" ref-type="fig">Fig. 6A&#x2013;6D</xref> and Supplementary Table S9 (<xref rid="dgae210-B38" ref-type="bibr">38</xref>)]. Some cLoF or pLoF variants (K71N, 102N, I102T, T150I, and F262L) also showed reduced ERK activation in response to &#x3B1;-MSH (all <italic toggle="yes">P</italic> &lt; .001). However, 3 pLoF variants (D37V, V95I, and V253I) displayed normal levels of ERK activation (<italic toggle="yes">P</italic> &gt; .05). Correspondingly, 2 WT-like variants (V255A and N274S) also had WT-like levels of ERK activation relative to WT (all <italic toggle="yes">P</italic> &gt; .05) in response to &#x3B1;-MSH. However, I195T, despite having a WT-like for cAMP response, showed a decrease in ERK activation (I195T <italic toggle="yes">P</italic> &lt; .001). Finally, the GoF variant C318Y also displayed increased &#x3B1;-MSH-induced activation of ERK (<italic toggle="yes">P</italic> &lt; .05).</p>
          <fig position="float" id="dgae210-F6" fig-type="figure">
            <label>Figure 6.</label>
            <caption>
              <p>Ligand-induced ERK activation in HEK293 cells transfected with the MC4R variants. Dose-response curves for &#x3B1;-MSH (A-D) and setmelanotide (E-H) were generated. ERK activation is expressed as Emax relative to WT MC4R (%WT). Emax (%WT) was compared between &#x3B1;-MSH and setmelanotide (I). The relative potency of setmelanotide is expressed as the EC<sub>50</sub> ratio of setmelanotide and &#x3B1;-MSH. For cLoF MC4R variants the EC<sub>50</sub> could be calculated; therefore the relative potentcy is expressed as n.d. (J). Values represent mean &#xB1; SEM from 3 to 4 independent experiments performed in duplicate. Statistical analysis was performed using unpaired two-tailed <italic toggle="yes">t</italic>-test; confidence level = 95%; <sup>*</sup><italic toggle="yes">P</italic> &#x2264; .05 and **<italic toggle="yes">P</italic> &#x2264; .001. Variants are ordered from cLoF, pLoF, WT-like, to GoF based on the &#x3B1;-MSH-induced cAMP response.</p>
              <p>Abbreviations: &#x3B1;-MSH, &#x3B1;-melanocyte stimulating hormone; cLoF, complete loss of function; EC<sub>50,</sub> median effective concentration; Emax, maximum effect; GoF, gain of function; HEK293, human embryonic kidney 293; MC4R, melanocortin-4 receptor; n.d., not determined; pLoF, partial loss of function; WT, wild type.</p>
            </caption>
            <graphic xlink:href="dgae210f6" position="float"/>
          </fig>
          <p>Stimulation of MC4R variants with setmelanotide resulted in a very similar pattern of ERK activation [<xref rid="dgae210-F6" ref-type="fig">Fig. 6E&#x2013;6H</xref> and Supplementary Table S9 (<xref rid="dgae210-B38" ref-type="bibr">38</xref>)] compared to &#x3B1;-MSH. Lastly, we calculated the relative potency of &#x3B1;-MSH and setmelanotide for these MC4R variants to activate ERK (<xref rid="dgae210-F6" ref-type="fig">Fig. 6J</xref>). Setmelanotide was approximately 10-fold more potent than &#x3B1;-MSH. However, for variants D37V, V95I, V253I, and N274S, the potency of setmelanotide relative to &#x3B1;-MSH was further enhanced by 25- to 50-fold.</p>
        </sec>
        <sec id="dgae210-s1.2.6">
          <title>The majority of the patients with <italic toggle="yes">MC4R</italic> variants displayed a severe genetic obesity phenotype</title>
          <p>There were 8 variants (I102N, I102T, T150I, W174X, F149YfsX9, M215R, C293Y, and P299H) that resulted in cLoF for the cAMP response from 6 pediatric patients and 2 adult patients (<xref rid="dgae210-T1" ref-type="table">Table 1</xref>). Four out of these 6 pediatric patients had the highest BMI SDS in our study, ranging from +4.3 to +7.2 SD. The remaining 2 patients had a BMI SDS +3.1 and +3.5. The 2 adult patients had a BMI of 55.5 and 56.2&#x2005;kg/m<sup>2</sup>, which were the highest in the adult group. The adult patient with the highest BMI (58.8&#x2005;kg/m<sup>2</sup>) had the D37V variant. It should be noted that this patient also carries the pathogenic Y35X <italic toggle="yes">MC4R</italic> variant and that the D37V is commonly found on a haplotype with this nonsense mutation (<xref rid="dgae210-B47" ref-type="bibr">47</xref>). Six out of 8 patients (2 adult and 4 pediatric) reported impaired satiety (<xref rid="dgae210-T1" ref-type="table">Table 1</xref>). Most reported an age of obesity onset &lt;5 years, while 1 patient reported an age of onset of 6.0 years. The age of obesity onset ranged between 0.3 and 6.0 years. All 8 patients reported obesity-related comorbidities [Supplementary Tables S3 and S4 (<xref rid="dgae210-B38" ref-type="bibr">38</xref>)]. The 4 patients (2 pediatric and 2 adult patients) with pLoF variants for cAMP response showed a less profound hyperphagic phenotype, severity of obesity, and obesity-related comorbidities.</p>
          <p>Besides the pediatric patient with a WT-like variant, I195T, showing no hyperphagia, the other 2 pediatric patients with WT-like variants exhibited a typical genetic obesity phenotype including an early age of onset of obesity and hyperphagia. All patients had similar obesity-related comorbidities compared to patients with cLoF variants. Lastly, the patient with a GoF variant for cAMP response, C318Y, displayed a BMI of 42.1&#x2005;kg/m<sup>2</sup>, early-onset obesity, and evident hyperphagia. At 28 years of age, the patient had numerous obesity-related comorbidities, such as hyperinsulinemia, dyslipidemia, hypertension, polycystic ovary syndrome, type 2 diabetes, and elevated liver enzymes.</p>
        </sec>
      </sec>
    </sec>
    <sec sec-type="discussion" id="dgae210-s2">
      <title>Discussion</title>
      <p>In this study, we functionally characterized 17, predominantly heterozygous, <italic toggle="yes">MC4R</italic> variants identified in our patients with early-onset severe obesity. Six of the variants are novel, 3 have not been functionally characterized, and 8 variants have been reported previously but were incompletely characterized and reported as variants of unknown significance, likely pathogenic or pathogenic, according to ACMG guidelines (<xref rid="dgae210-T2" ref-type="table">Table 2</xref>). We studied the response of these variant receptors to its endogenous ligand &#x3B1;-MSH but also to the synthetic agonist setmelanotide (<xref rid="dgae210-F7" ref-type="fig">Fig. 7</xref>). Setmelanotide has been approved by the Food and Drug Administration and European Medicines Agency for treatment of rare monogenic obesity caused by pathogenic variants in genes upstream of <italic toggle="yes">MC4R</italic> (<xref rid="dgae210-B48" ref-type="bibr">48</xref>, <xref rid="dgae210-B49" ref-type="bibr">49</xref>). However, because setmelanotide has a greater potency for MC4R than &#x3B1;-MSH (<xref rid="dgae210-B35" ref-type="bibr">35</xref>, <xref rid="dgae210-B50" ref-type="bibr">50</xref>), we analyzed whether setmelanotide could rescue signaling of the <italic toggle="yes">MC4R</italic> variants. Recent studies have shown that MC4R signaling can be mediated through several signaling pathways (<xref rid="dgae210-B30" ref-type="bibr">30</xref>, <xref rid="dgae210-B51" ref-type="bibr">51</xref>). Pathogenic MC4R variants may therefore result in biased signaling (<xref rid="dgae210-B27" ref-type="bibr">27</xref>), changing the response to its agonists and/or affecting only a subset of the downstream signaling pathways. Here we show that several of the studied MC4R variants differentially impact downstream signaling and the response to setmelanotide.</p>
      <fig position="float" id="dgae210-F7" fig-type="figure">
        <label>Figure 7.</label>
        <caption>
          <p>Summary of the effects of the MC4R variants on cell surface expression and &#x3B1;-MSH- or setmelanotide-induced cAMP response, ERK activation, and &#x3B2;-arrestin-2 recruitment. Variants are ordered from pLoF, WT-like, to GoF based on the &#x3B1;-MSH-induced cAMP response.</p>
          <p>Abbreviations: &#x3B1;-MSH, &#x3B1;-melanocyte stimulating hormone; GoF, gain of function; MC4R, melanocortin-4 receptor; pLoF, partial loss of function; WT, wild type.</p>
        </caption>
        <graphic xlink:href="dgae210f7" position="float"/>
      </fig>
      <p>We identified 5 <italic toggle="yes">MC4R</italic> variants, 2 nonsense (F149YfsX9 and W174X) and 3 missense (P299H, M215R, and C293Y) variants, with a complete loss of cell surface expression. As expected, this also resulted in a complete loss of cAMP signaling and &#x3B2;-arrestin-2 recruitment in response to both &#x3B1;-MSH and setmelanotide. Thus these variants lead to a complete loss of function for all signaling pathways studied here and should be considered pathogenic and causative of obesity.</p>
      <p>The other <italic toggle="yes">MC4R</italic> variants, however, showed a large heterogeneity in effects on studied endpoints (<xref rid="dgae210-F7" ref-type="fig">Fig. 7</xref>). Five variants (D37V, K71N, I102T, T150I, and I195T) showed reduced levels of cell surface expression combined with reduced total expression for most of them, likely resulting from impaired receptor trafficking (<xref rid="dgae210-B52" ref-type="bibr">52</xref>, <xref rid="dgae210-B53" ref-type="bibr">53</xref>).</p>
      <p>The variants K71N, I102T, and T150I also resulted in complete or partial loss of cAMP signaling with either normal or loss of &#x3B2;-arrestin-2 recruitment in response to &#x3B1;-MSH. However, K71N displayed significantly increased basal rates of &#x3B2;-arrestin-2 recruitment. This likely causes constitutive internalization and desensitization of the receptor (<xref rid="dgae210-B54" ref-type="bibr">54</xref>), which is in line with the reduced cAMP signaling observed for this variant. T150I has been investigated previously, with similar outcomes to our study apart from showing a reduced &#x3B2;-arrestin-2 recruitment (<xref rid="dgae210-B27" ref-type="bibr">27</xref>). A previous study identified I102T in normal weight subjects and functionally characterized it as a LoF variant based on reduced signaling and ligand binding (<xref rid="dgae210-B55" ref-type="bibr">55</xref>), which our detailed functional analysis is in agreement with. I195T, despite having a lower cell surface expression, showed an &#x3B1;-MSH-induced cAMP response comparable to WT MC4R. This variant, however, was defective in &#x3B2;-arrestin-2 recruitment. We speculate that the receptor may have greater turnover at the cell surface, explaining the normal cAMP response in vitro. Another explanation could be that there are spare receptors in the in vitro assay system, as suggested by Tao (<xref rid="dgae210-B56" ref-type="bibr">56</xref>). Spare receptors may still be able to respond to the ligand with maximum efficacy despite the reduction in surface expression caused by the I195T variant. However, the mechanism for this needs further investigation.</p>
      <p>The remaining 7 variants had normal or increased cell surface expression with variable effects on cAMP response and &#x3B2;-arrestin-2 recruitment. Two of these variants (V255A and N274S) were comparable to WT MC4R for all pathways studied, which for N274S is in line with previous studies (<xref rid="dgae210-B30" ref-type="bibr">30</xref>, <xref rid="dgae210-B57" ref-type="bibr">57</xref>). This raises the question whether these variants are pathogenic and thus associated with the obesity phenotype. Although clinically indistinguishable from patients carrying cLoF <italic toggle="yes">MC4R</italic> variants, there could still be alternative causes, including an unidentified variant in a different gene, polygenic obesity, or epigenetics. It should be noted that in a previous study V255A was reported to have a pLoF in cAMP response (75% Emax) and decreased binding (&#x223C;60%) to &#x3B1;-MSH compared to the WT receptor, although only the latter was significantly different from WT MC4R (<xref rid="dgae210-B58" ref-type="bibr">58</xref>). Assay differences to measure cAMP possibly account for this difference.</p>
      <p>It is also possible that other aspects of MC4R signaling should be studied to determine whether these are indeed pathogenic variants. It has been suggested that MC4R might signal through ERK (<xref rid="dgae210-B59" ref-type="bibr">59-63</xref>). However, for V255A and N274S, &#x3B1;-MSH-induced ERK activation was comparable to activation by WT MC4R. In general, we observed that for all cell-surface expressed variants studied, the direction of effect of MC4R variants on ERK signaling was largely similar to that of the cAMP response and independent of the &#x3B2;-arrestin-2 recruitment findings. Variants with less than 80% &#x3B1;-MSH-induced cAMP response also displayed a strongly diminished ERK activation (&lt;50%). However, variants with a partial reduction in cAMP response only mildly affected ERK signaling. This suggests that assessment of the cAMP response is more informative in determining the functional consequence of a variant.</p>
      <p>Our results also suggest that the ERK and cAMP responses are likely both mediated through G&#x3B1;<sub>s</sub> and are not independent MC4R signaling events (<xref rid="dgae210-B30" ref-type="bibr">30</xref>). We should be cautious to rule out biased effects on cAMP and ERK signaling as other variants may have different effects (<xref rid="dgae210-B58" ref-type="bibr">58</xref>, <xref rid="dgae210-B64" ref-type="bibr">64</xref>). For instance, it has been reported that several MC4R variants, such as H76R, H158R, and L250Q, have normal ligand-induced ERK1/2 activity but constitutive activity for cAMP production (<xref rid="dgae210-B64" ref-type="bibr">64</xref>, <xref rid="dgae210-B65" ref-type="bibr">65</xref>). Furthermore, ERK1/2 activity has also been shown to be induced by the G&#x3B1;<sub>q</sub>/Ca<sup>2+</sup> signaling pathway for other G-protein coupled receptors (<xref rid="dgae210-B66" ref-type="bibr">66</xref>, <xref rid="dgae210-B67" ref-type="bibr">67</xref>). There is also evidence that MC4R can signal via Ca<sup>2+</sup> ions (<xref rid="dgae210-B25" ref-type="bibr">25</xref>, <xref rid="dgae210-B68" ref-type="bibr">68</xref>). Although G&#x3B1;<sub>s</sub> seems to be essential for ERK signaling, it could be that recruitment of other G proteins by MC4R could modulate this pathway. In addition, homo- and/or hetero-receptor dimerization (<xref rid="dgae210-B69" ref-type="bibr">69</xref>) and interactions with MRAP2 (<xref rid="dgae210-B70" ref-type="bibr">70</xref>) could be affected by the variants leading to altered biological function, but this remains to be explored.</p>
      <p>Surprisingly, we identified 1 variant, C318Y, with a gain of function in cAMP response to both agonists. This variant is located in intracellular helix 8, shown to be important for proper cell surface localization and modulation of &#x3B2;-arrestin-2 binding (<xref rid="dgae210-B71" ref-type="bibr">71</xref>, <xref rid="dgae210-B72" ref-type="bibr">72</xref>). The C318 residue has previously been shown to be lipid-modified, which may stabilize cell surface expression and the signaling capacity (<xref rid="dgae210-B73" ref-type="bibr">73</xref>). Truncation of the receptor before C318 impaired cell surface expression, while truncation after C318 resulted in a normally expressed and functioning receptor. Truncation at C318 results in a receptor that can signal, although the receptor was rapidly internalized and cell surface expression could not easily be detected (<xref rid="dgae210-B73" ref-type="bibr">73</xref>). Interestingly, the C318Y variant in our study caused a complete loss of &#x3B2;-arrestin-2 recruitment. We speculate that this results in retention of the receptor in the plasma membrane, explaining the increased signaling observed for this variant and underscoring the critical role of C318 in receptor function. However, the gain of function of this variant does not match with the obese phenotype of the patient as increased MC4R signaling is proposed to be associated with a lean phenotype (<xref rid="dgae210-B27" ref-type="bibr">27</xref>).</p>
      <p>Previously, MC4R variants, such as H76R, have been identified in patients with obesity that displayed constitutive activity, although some of these variants could not be further stimulated with &#x3B1;-MSH (<xref rid="dgae210-B65" ref-type="bibr">65</xref>). In a study by Lotta et al, GoF <italic toggle="yes">MC4R</italic> variants were associated with significantly decreased BMI and risk of type 2 diabetes and coronary artery disease (<xref rid="dgae210-B27" ref-type="bibr">27</xref>). The authors concluded that these beneficial associations are driven by increased &#x3B2;-arrestin-2 recruitment, rather than cAMP signaling.</p>
      <p>At least 2 other obesogenic MC4R variants, R236C and T101N, have been described that, like C318Y, show bias toward the cAMP response, a suppressed ability to recruit &#x3B2;-arrestin-2, and increased cell surface expression (<xref rid="dgae210-B27" ref-type="bibr">27</xref>, <xref rid="dgae210-B74" ref-type="bibr">74</xref>, <xref rid="dgae210-B75" ref-type="bibr">75</xref>). The effects of these variants reinforces the concept that &#x3B2;-arrestin-2 recruitment plays an important role in the regulation of body weight. However, the counterintuitive relationship these variants show between increased cAMP signaling and BMI demonstrates that further studies are needed to unravel the mechanism of their association with obesity. The use of patient-derived iPSC cells would aid to identify other pathogenic mechanisms, as it would allow the study the variant in the patient's own genetic background.</p>
      <p>Despite the range of effects these variants had on the studied signaling pathways, we did not observe a clear correlation with the phenotype, although 6 out of 8 patients with cLoF variants for cAMP response had the highest BMIs. This could be explained by the fact that only patients with severe obesity and a medical or family history suggesting genetic obesity are referred to our clinic, and genetic screening is only performed when certain genetic obesity features are present. We observed that the majority of the patients displayed obesity-related comorbidities despite their young age at assessment. Furthermore, since we only had 1 patient per genotype, we are also unable to determine the penetrance of most of the variants. This is of interest, since recent studies indicate that other genetic factors contribute to the phenotype. For instance, a UK Biobank study showed that carriers of pathogenic <italic toggle="yes">MC4R</italic> variants with normal weight had a significantly lower polygenic risk score for BMI, compared to carriers with obesity (<xref rid="dgae210-B76" ref-type="bibr">76</xref>). This illustrates that the polygenic background can modify the disease penetrance of monogenic variants.</p>
      <p>Studies have shown that setmelanotide can be a potent weight loss therapy for patients with bi/allelic pathogenic <italic toggle="yes">LEPR</italic> and <italic toggle="yes">POMC</italic> variants (<xref rid="dgae210-B77" ref-type="bibr">77</xref>). However, it is still unclear whether setmelanotide can lead to clinically relevant weight loss in patients carrying heterozygous pathogenic <italic toggle="yes">MC4R</italic> variants. Our study confirms that setmelanotide has a markedly greater potency, but similar efficacy, to &#x3B1;-MSH for WT MC4R cAMP signaling (<xref rid="dgae210-B35" ref-type="bibr">35</xref>, <xref rid="dgae210-B46" ref-type="bibr">46</xref>), &#x3B2;-arrestin-2 recruitment, and ERK signaling. Thus, setmelanotide might potentiate the response of the unaffected allele and thereby be effective in heterozygous carriers. Indeed, heterozygous <italic toggle="yes">Mc4r</italic> knockout mice lose weight on setmelanotide treatment although they are less sensitive than WT mice (<xref rid="dgae210-B35" ref-type="bibr">35</xref>). A study with a small group of patients harboring heterozygous <italic toggle="yes">MC4R</italic> variants showed that setmelanotide treatment resulted in weight loss (<xref rid="dgae210-B35" ref-type="bibr">35</xref>). The precise mechanisms remains to be determined as it has also been suggested that agonists might restore the expression of mutant receptors at the cell surface (<xref rid="dgae210-B35" ref-type="bibr">35</xref>). Whether setmelanotide elicits this effect on all or certain <italic toggle="yes">MC4R</italic> variants remains to be determined.</p>
      <p>For most of the variants, we noticed that the cAMP Emax response to setmelanotide and &#x3B1;-MSH were similarly affected. However, for both I102N and I102T, setmelanotide improved the efficacy of the receptor to induce cAMP. In particular for I102T, stimulation with setmelanotide changed the cAMP response from a cLoF to a pLoF. Combined with the complete loss of &#x3B2;-arrestin-2 recruitment that these variants displayed for &#x3B1;-MSH and setmelanotide, this may suggest that setmelanotide may partially rescue signaling of these variants. Interestingly, the I102 variants are located close to the ligand binding pocket, particularly T101, which interacts directly with &#x3B1;-MSH and setmelanotide via a hydrogen bond (<xref rid="dgae210-B25" ref-type="bibr">25</xref>, <xref rid="dgae210-B78" ref-type="bibr">78</xref>). Moreover, variants at T100 and V103 that are more responsive to ligand were recently shown to alter the conformation of setmelanotide allowing it to fit within the ligand binding pocket and/or to increase the binding affinity of setmelanotide (<xref rid="dgae210-B46" ref-type="bibr">46</xref>). This also applies to the K71N and I195T variants. Setmelanotide did not alter the constitutive &#x3B2;-arrestin-2 recruitment of K71N; however, this variant significantly reduced the efficacy and potency of setmelanotide for cAMP signaling. I195T also displayed a reduced potency for setmelanotide-induced cAMP signaling. These results indicate that detailed analysis of distinct <italic toggle="yes">MC4R</italic> variants is needed to determine whether setmelanotide has beneficial effects beyond bi/allelic <italic toggle="yes">POMC</italic>, <italic toggle="yes">PCSK1</italic>, and <italic toggle="yes">LEPR</italic> loss of function variants. This could then be extended to clinical studies of patients with specific variants.</p>
      <p>In conclusion, our study highlights the importance of studying the effect of variants on multiple aspects of MC4R signaling to fully understand the impact of a specific variant. In silico tools to predict the effects of these variants can be insufficient, as information on various signaling pathways is still incomplete. Indeed, our functional analyses show that several of the MC4R variants reported as likely pathogenic or of unknown significance according to the ACMG guidelines are partial or complete LoF variants (<xref rid="dgae210-T2" ref-type="table">Table 2</xref>). We have categorized these variants based on the &#x3B1;-MSH induced cAMP response and also according to the molecular classification of MC4R mutations proposed by Tao (<xref rid="dgae210-B56" ref-type="bibr">56</xref>), which indicates the functional consequence of the variants (<xref rid="dgae210-T2" ref-type="table">Table 2</xref>). Knowledge about the impact of a distinct <italic toggle="yes">MC4R</italic> variant on MC4R signaling may aid in selecting the best personalized obesity treatment option. Although setmelanotide is less effective in patients with pathogenic <italic toggle="yes">MC4R</italic> variants, knowledge about the effect of a certain variant on the setmelanotide response may aid in identifying those patients that might benefit from this targeted pharmacological treatment.</p>
    </sec>
  </body>
  <back>
    <ack id="ack1">
      <title>Acknowledgments</title>
      <p>We would like to thank all patients and caregivers who participated in the study.</p>
    </ack>
    <sec id="dgae210-s3">
      <title>Author Contributions</title>
      <p>A.R., E.v.d.A., E.v.R., P.D., and J.V. contributed to the study design; M.v.H., E.B., M.W., E.v.d.A., and E.v.R., contributed to patient data collection and analysis; A.R. performed experiments; A.R., P.D., and J.V. contributed to data interpretation; A.R. prepared the figures; A.R., P.D., and J.V. drafted the manuscript; A.R., P.D., and J.V. edited and revised the manuscript. All authors made revisions and approved the final version of the manuscript.</p>
    </sec>
    <sec id="dgae210-s4">
      <title>Disclosures</title>
      <p>J.V. has received royalties from AMH assays, paid to the institute/laboratory with no personal financial gain. E.v.d.A. has research contracts with Rhythm for the clinical trials with setmelanotide. All payments are made to the institute with no personal financial gain. E.v.R. is coinvestigator on these clinical setmelanotide trials, supported by Rhythm, and also receives no personal financial support. A.R., M.W., E.B., M.v.H., and P.D. have no conflicts of interest.</p>
    </sec>
    <sec sec-type="data-availability" id="dgae210-s5">
      <title>Data Availability</title>
      <p>Restrictions apply to the availability of some or all data generated or analyzed during this study to preserve patient confidentiality. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided.</p>
    </sec>
    <ref-list id="ref1">
      <title>References</title>
      <ref id="dgae210-B1">
        <label>1</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gavini</surname>
<given-names>CK</given-names>
</string-name>, <string-name><surname>Cook</surname><given-names>TM</given-names></string-name>, <string-name><surname>Rademacher</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Mansuy-Aubert</surname><given-names>V</given-names></string-name></person-group>. <article-title>Hypothalamic C2-domain protein involved in MC4R trafficking and control of energy balance</article-title>. <source>Metabolism</source>. <year>2020</year>;<volume>102</volume>:<fpage>153990</fpage>.<pub-id pub-id-type="pmid">31666192</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B2">
        <label>2</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kleinendorst</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Massink</surname><given-names>MPG</given-names></string-name>, <string-name><surname>Cooiman</surname><given-names>MI</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Genetic obesity: next-generation sequencing results of 1230 patients with obesity</article-title>. <source>J Med Genet</source>. <year>2018</year>;<volume>55</volume>(<issue>9</issue>):<fpage>578</fpage>&#x2010;<lpage>586</lpage>.<pub-id pub-id-type="pmid">29970488</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B3">
        <label>3</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bray</surname>
<given-names>GA</given-names>
</string-name>, <string-name><surname>Kim</surname><given-names>KK</given-names></string-name>, <string-name><surname>Wilding</surname><given-names>JPH</given-names></string-name>, <string-name><surname>World Obesity</surname><given-names>F</given-names></string-name></person-group>. <article-title>Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation</article-title>. <source>Obes Rev</source>. <year>2017</year>;<volume>18</volume>(<issue>7</issue>):<fpage>715</fpage>&#x2010;<lpage>723</lpage>.<pub-id pub-id-type="pmid">28489290</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B4">
        <label>4</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Farooqi</surname>
<given-names>IS</given-names>
</string-name>, <string-name><surname>Keogh</surname><given-names>JM</given-names></string-name>, <string-name><surname>Yeo</surname><given-names>GS</given-names></string-name>, <string-name><surname>Lank</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Cheetham</surname><given-names>T</given-names></string-name>, <string-name><surname>O'Rahilly</surname><given-names>S</given-names></string-name></person-group>. <article-title>Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene</article-title>. <source>N Engl J Med</source>. <year>2003</year>;<volume>348</volume>(<issue>12</issue>):<fpage>1085</fpage>&#x2010;<lpage>1095</lpage>.<pub-id pub-id-type="pmid">12646665</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B5">
        <label>5</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Polderman</surname>
<given-names>TJ</given-names>
</string-name>, <string-name><surname>Benyamin</surname><given-names>B</given-names></string-name>, <string-name><surname>de Leeuw</surname><given-names>CA</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Meta-analysis of the heritability of human traits based on fifty years of twin studies</article-title>. <source>Nat Genet</source>. <year>2015</year>;<volume>47</volume>(<issue>7</issue>):<fpage>702</fpage>&#x2010;<lpage>709</lpage>.<pub-id pub-id-type="pmid">25985137</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B6">
        <label>6</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Farooqi</surname>
<given-names>IS</given-names>
</string-name>
</person-group>. <article-title>EJE prize 2012: obesity: from genes to behaviour</article-title>. <source>Eur J Endocrinol</source>. <year>2014</year>;<volume>171</volume>(<issue>5</issue>):<fpage>R191</fpage>&#x2010;<lpage>R195</lpage>.<pub-id pub-id-type="pmid">25127711</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B7">
        <label>7</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ignatieva</surname>
<given-names>EV</given-names>
</string-name>, <string-name><surname>Afonnikov</surname><given-names>DA</given-names></string-name>, <string-name><surname>Saik</surname><given-names>OV</given-names></string-name>, <string-name><surname>Rogaev</surname><given-names>EI</given-names></string-name>, <string-name><surname>Kolchanov</surname><given-names>NA</given-names></string-name></person-group>. <article-title>A compendium of human genes regulating feeding behavior and body weight, its functional characterization and identification of GWAS genes involved in brain-specific PPI network</article-title>. <source>BMC Genet</source>. <year>2016</year>;<volume>17</volume>(<issue>S3</issue>):<fpage>158</fpage>.<pub-id pub-id-type="pmid">28105929</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B8">
        <label>8</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yong</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Cakir</surname><given-names>I</given-names></string-name>, <string-name><surname>Lining Pan</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Endogenous cannabinoids are required for MC4R-mediated control of energy homeostasis</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2021</year>;<volume>118</volume>(<issue>42</issue>):<comment>e2015990118</comment>.</mixed-citation>
      </ref>
      <ref id="dgae210-B9">
        <label>9</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sweeney</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name><surname>Rajapakse</surname><given-names>I</given-names></string-name>, <string-name><surname>Cone</surname><given-names>RD</given-names></string-name></person-group>. <article-title>Network dynamics of hypothalamic feeding neurons</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2021</year>;<volume>118</volume>(<issue>14</issue>):<comment>e2011140118</comment>.</mixed-citation>
      </ref>
      <ref id="dgae210-B10">
        <label>10</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tao</surname>
<given-names>YX</given-names>
</string-name>
</person-group>. <article-title>The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology</article-title>. <source>Endocr Rev</source>. <year>2010</year>;<volume>31</volume>(<issue>4</issue>):<fpage>506</fpage>&#x2010;<lpage>543</lpage>.<pub-id pub-id-type="pmid">20190196</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B11">
        <label>11</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Doulla</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>McIntyre</surname><given-names>AD</given-names></string-name>, <string-name><surname>Hegele</surname><given-names>RA</given-names></string-name>, <string-name><surname>Gallego</surname><given-names>PH</given-names></string-name></person-group>. <article-title>A novel MC4R mutation associated with childhood-onset obesity: a case report</article-title>. <source>Paediatr Child Health</source>. <year>2014</year>;<volume>19</volume>(<issue>10</issue>):<fpage>515</fpage>&#x2010;<lpage>518</lpage>.<pub-id pub-id-type="pmid">25587224</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B12">
        <label>12</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Delhanty</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Bouw</surname><given-names>E</given-names></string-name>, <string-name><surname>Huisman</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Functional characterization of a new human melanocortin-4 receptor homozygous mutation (N72K) that is associated with early-onset obesity</article-title>. <source>Mol Biol Rep</source>. <year>2014</year>;<volume>41</volume>(<issue>12</issue>):<fpage>7967</fpage>&#x2010;<lpage>7972</lpage>.<pub-id pub-id-type="pmid">25163632</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B13">
        <label>13</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Stutzmann</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Tan</surname><given-names>K</given-names></string-name>, <string-name><surname>Vatin</surname><given-names>V</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees</article-title>. <source>Diabetes</source>. <year>2008</year>;<volume>57</volume>(<issue>9</issue>):<fpage>2511</fpage>&#x2010;<lpage>2518</lpage>.<pub-id pub-id-type="pmid">18559663</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B14">
        <label>14</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>O'Rahilly</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Farooqi</surname><given-names>IS</given-names></string-name></person-group>. <article-title>Genetics of obesity</article-title>. <source>Philos Trans R Soc Lond B Biol Sci</source>. <year>2006</year>;<volume>361</volume>(<issue>1471</issue>):<fpage>1095</fpage>&#x2010;<lpage>1105</lpage>.<pub-id pub-id-type="pmid">16815794</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B15">
        <label>15</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Santoro</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Cirillo</surname><given-names>G</given-names></string-name>, <string-name><surname>Xiang</surname><given-names>Z</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Prevalence of pathogenetic MC4R mutations in Italian children with early onset obesity, tall stature and familial history of obesity</article-title>. <source>BMC Med Genet</source>. <year>2009</year>;<volume>10</volume>(<issue>1</issue>):<fpage>25</fpage>.<pub-id pub-id-type="pmid">19284607</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B16">
        <label>16</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Huszar</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Lynch</surname><given-names>CA</given-names></string-name>, <string-name><surname>Fairchild-Huntress</surname><given-names>V</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Targeted disruption of the melanocortin-4 receptor results in obesity in mice</article-title>. <source>Cell</source>. <year>1997</year>;<volume>88</volume>(<issue>1</issue>):<fpage>131</fpage>&#x2010;<lpage>141</lpage>.<pub-id pub-id-type="pmid">9019399</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B17">
        <label>17</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Harrold</surname>
<given-names>JA</given-names>
</string-name>, <string-name><surname>Williams</surname><given-names>G</given-names></string-name></person-group>. <article-title>Melanocortin-4 receptors, beta-MSH and leptin: key elements in the satiety pathway</article-title>. <source>Peptides</source>. <year>2006</year>;<volume>27</volume>(<issue>2</issue>):<fpage>365</fpage>&#x2010;<lpage>371</lpage>.<pub-id pub-id-type="pmid">16290320</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B18">
        <label>18</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fani</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Bak</surname><given-names>S</given-names></string-name>, <string-name><surname>Delhanty</surname><given-names>P</given-names></string-name>, <string-name><surname>van Rossum</surname><given-names>EFC</given-names></string-name>, <string-name><surname>van den Akker</surname><given-names>ELT</given-names></string-name></person-group>. <article-title>The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options</article-title>. <source>Int J Obesity</source>. <year>2014</year>;<volume>38</volume>(<issue>2</issue>):<fpage>163</fpage>&#x2010;<lpage>169</lpage>.</mixed-citation>
      </ref>
      <ref id="dgae210-B19">
        <label>19</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>MacKenzie</surname>
<given-names>RG</given-names>
</string-name>
</person-group>. <article-title>Obesity-associated mutations in the human melanocortin-4 receptor gene</article-title>. <source>Peptides</source>. <year>2006</year>;<volume>27</volume>(<issue>2</issue>):<fpage>395</fpage>&#x2010;<lpage>403</lpage>.<pub-id pub-id-type="pmid">16274851</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B20">
        <label>20</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lubrano-Berthelier</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Cavazos</surname><given-names>M</given-names></string-name>, <string-name><surname>Dubern</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Molecular genetics of human obesity-associated MC4R mutations</article-title>. <source>Ann N Y Acad Sci</source>. <year>2003</year>;<volume>994</volume>(<issue>1</issue>):<fpage>49</fpage>&#x2010;<lpage>57</lpage>.<pub-id pub-id-type="pmid">12851297</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B21">
        <label>21</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hinney</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Volckmar</surname><given-names>AL</given-names></string-name>, <string-name><surname>Knoll</surname><given-names>N</given-names></string-name></person-group>. <article-title>Melanocortin-4 receptor in energy homeostasis and obesity pathogenesis</article-title>. <source>Prog Mol Biol Transl Sci</source>. <year>2013</year>;<volume>114</volume>:<fpage>147</fpage>&#x2010;<lpage>191</lpage>.<pub-id pub-id-type="pmid">23317785</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B22">
        <label>22</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Drabkin</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Birk</surname><given-names>OS</given-names></string-name>, <string-name><surname>Birk</surname><given-names>R</given-names></string-name></person-group>. <article-title>Heterozygous versus homozygous phenotype caused by the same MC4R mutation: novel mutation affecting a large consanguineous kindred</article-title>. <source>BMC Med Genet</source>. <year>2018</year>;<volume>19</volume>(<issue>1</issue>):<fpage>135</fpage>.<pub-id pub-id-type="pmid">30068297</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B23">
        <label>23</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wade</surname>
<given-names>KH</given-names>
</string-name>, <string-name><surname>Lam</surname><given-names>BYH</given-names></string-name>, <string-name><surname>Melvin</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Loss-of-function mutations in the melanocortin 4 receptor in a UK birth cohort</article-title>. <source>Nat Med</source>. <year>2021</year>;<volume>27</volume>(<issue>6</issue>):<fpage>1088</fpage>&#x2010;<lpage>1096</lpage>.<pub-id pub-id-type="pmid">34045736</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B24">
        <label>24</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rene</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Lanfray</surname><given-names>D</given-names></string-name>, <string-name><surname>Richard</surname><given-names>D</given-names></string-name>, <string-name><surname>Bouvier</surname><given-names>M</given-names></string-name></person-group>. <article-title>Pharmacological chaperone action in humanized mouse models of MC4R-linked obesity</article-title>. <source>JCI Insight</source>. <year>2021</year>;<volume>6</volume>(<issue>4</issue>):<fpage>e132778</fpage>.<pub-id pub-id-type="pmid">33434184</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B25">
        <label>25</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Heyder</surname>
<given-names>NA</given-names>
</string-name>, <string-name><surname>Kleinau</surname><given-names>G</given-names></string-name>, <string-name><surname>Speck</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Structures of active melanocortin-4 receptor-Gs-protein complexes with NDP-alpha-MSH and setmelanotide</article-title>. <source>Cell Res</source>. <year>2021</year>;<volume>31</volume>(<issue>11</issue>):<fpage>1176</fpage>&#x2010;<lpage>1189</lpage>.<pub-id pub-id-type="pmid">34561620</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B26">
        <label>26</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gillyard</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Fowler</surname><given-names>K</given-names></string-name>, <string-name><surname>Williams</surname><given-names>SY</given-names></string-name>, <string-name><surname>Cone</surname><given-names>RD</given-names></string-name></person-group>. <article-title>Obesity-associated mutant melanocortin-4 receptors with normal Galphas coupling frequently exhibit other discoverable pharmacological and biochemical defects</article-title>. <source>J Neuroendocrinol</source>. <year>2019</year>;<volume>31</volume>(<issue>10</issue>):<fpage>e12795</fpage>.<pub-id pub-id-type="pmid">31529534</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B27">
        <label>27</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lotta</surname>
<given-names>LA</given-names>
</string-name>, <string-name><surname>Mokrosinski</surname><given-names>J</given-names></string-name>, <string-name><surname>de Oliveira E</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Human gain-of-function MC4R variants show signaling bias and protect against obesity</article-title>. <source>Cell</source>. <year>2019</year>;<volume>177</volume>(<issue>3</issue>):<fpage>597</fpage>&#x2010;<lpage>607 e599</lpage>.<pub-id pub-id-type="pmid">31002796</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B28">
        <label>28</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rajagopal</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Shenoy</surname><given-names>SK</given-names></string-name></person-group>. <article-title>GPCR desensitization: acute and prolonged phases</article-title>. <source>Cell Signal</source>. <year>2018</year>;<volume>41</volume>:<fpage>9</fpage>&#x2010;<lpage>16</lpage>.<pub-id pub-id-type="pmid">28137506</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B29">
        <label>29</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fessikh M</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Belghiti</surname><given-names>H</given-names></string-name>, <string-name><surname>Elkarhat</surname><given-names>Z</given-names></string-name>, <string-name><surname>Guerinech</surname><given-names>H</given-names></string-name>, <string-name><surname>Dakka</surname><given-names>N</given-names></string-name>, <string-name><surname>El Baghdadi</surname><given-names>J</given-names></string-name></person-group>. <article-title>Identification of p.Met215Ile mutation of the MC4R gene in a Moroccan woman with obesity</article-title>. <source>Clin Case Rep</source>. <year>2021</year>;<volume>9</volume>(<issue>11</issue>):<fpage>e05059</fpage>.<pub-id pub-id-type="pmid">34815872</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B30">
        <label>30</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Brouwers</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>de Oliveira</surname><given-names>EM</given-names></string-name>, <string-name><surname>Marti-Solano</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Human MC4R variants affect endocytosis, trafficking and dimerization revealing multiple cellular mechanisms involved in weight regulation</article-title>. <source>Cell Rep</source>. <year>2021</year>;<volume>34</volume>(<issue>12</issue>):<fpage>108862</fpage>.<pub-id pub-id-type="pmid">33761344</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B31">
        <label>31</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Damm</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Buech</surname><given-names>TR</given-names></string-name>, <string-name><surname>Gudermann</surname><given-names>T</given-names></string-name>, <string-name><surname>Breit</surname><given-names>A</given-names></string-name></person-group>. <article-title>Melanocortin-induced PKA activation inhibits AMPK activity via ERK-1/2 and LKB-1 in hypothalamic GT1-7 cells</article-title>. <source>Mol Endocrinol</source>. <year>2012</year>;<volume>26</volume>(<issue>4</issue>):<fpage>643</fpage>&#x2010;<lpage>654</lpage>.<pub-id pub-id-type="pmid">22361823</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B32">
        <label>32</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ramirez</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Saba</surname><given-names>J</given-names></string-name>, <string-name><surname>Carniglia</surname><given-names>L</given-names></string-name>, <string-name><surname>Durand</surname><given-names>D</given-names></string-name>, <string-name><surname>Lasaga</surname><given-names>M</given-names></string-name>, <string-name><surname>Caruso</surname><given-names>C</given-names></string-name></person-group>. <article-title>Melanocortin 4 receptor activates ERK-cFos pathway to increase brain-derived neurotrophic factor expression in rat astrocytes and hypothalamus</article-title>. <source>Mol Cell Endocrinol</source>. <year>2015</year>;<volume>411</volume>:<fpage>28</fpage>&#x2010;<lpage>37</lpage>.<pub-id pub-id-type="pmid">25892444</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B33">
        <label>33</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sutton</surname>
<given-names>GM</given-names>
</string-name>, <string-name><surname>Duos</surname><given-names>B</given-names></string-name>, <string-name><surname>Patterson</surname><given-names>LM</given-names></string-name>, <string-name><surname>Berthoud</surname><given-names>HR</given-names></string-name></person-group>. <article-title>Melanocortinergic modulation of cholecystokinin-induced suppression of feeding through extracellular signal-regulated kinase signaling in rat solitary nucleus</article-title>. <source>Endocrinology</source>. <year>2005</year>;<volume>146</volume>(<issue>9</issue>):<fpage>3739</fpage>&#x2010;<lpage>3747</lpage>.<pub-id pub-id-type="pmid">15961554</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B34">
        <label>34</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kuhnen</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Krude</surname><given-names>H</given-names></string-name>, <string-name><surname>Biebermann</surname><given-names>H</given-names></string-name></person-group>. <article-title>Melanocortin-4 receptor signalling: importance for weight regulation and obesity treatment</article-title>. <source>Trends Mol Med</source>. <year>2019</year>;<volume>25</volume>(<issue>2</issue>):<fpage>136</fpage>&#x2010;<lpage>148</lpage>.<pub-id pub-id-type="pmid">30642682</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B35">
        <label>35</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Collet</surname>
<given-names>TH</given-names>
</string-name>, <string-name><surname>Dubern</surname><given-names>B</given-names></string-name>, <string-name><surname>Mokrosinski</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Evaluation of a melanocortin-4 receptor (MC4R) agonist (setmelanotide) in MC4R deficiency</article-title>. <source>Mol Metab</source>. <year>2017</year>;<volume>6</volume>(<issue>10</issue>):<fpage>1321</fpage>&#x2010;<lpage>1329</lpage>.<pub-id pub-id-type="pmid">29031731</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B36">
        <label>36</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ayers</surname>
<given-names>KL</given-names>
</string-name>, <string-name><surname>Glicksberg</surname><given-names>BS</given-names></string-name>, <string-name><surname>Garfield</surname><given-names>AS</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Melanocortin 4 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2018</year>;<volume>103</volume>(<issue>7</issue>):<fpage>2601</fpage>&#x2010;<lpage>2612</lpage>.<pub-id pub-id-type="pmid">29726959</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B37">
        <label>37</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Clement</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Biebermann</surname><given-names>H</given-names></string-name>, <string-name><surname>Farooqi</surname><given-names>IS</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency</article-title>. <source>Nat Med</source>. <year>2018</year>;<volume>24</volume>(<issue>5</issue>):<fpage>551</fpage>&#x2010;<lpage>555</lpage>.<pub-id pub-id-type="pmid">29736023</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B38">
        <label>38</label>
        <mixed-citation publication-type="data">
<person-group person-group-type="author">
<string-name>
<surname>Rodr&#xED;guez Rond&#xF3;n</surname>
<given-names>AV</given-names>
</string-name>, <string-name><surname>Welling</surname><given-names>MS</given-names></string-name>, <string-name><surname>van den Akker</surname><given-names>ELT</given-names></string-name>, <etal>et al</etal></person-group>
<data-title>Data from: MC4R variants modulate &#x3B1;-MSH and setmelanotide induced cellular signaling at multiple levels</data-title>. <italic toggle="yes">Figshare</italic>. Date of Deposit December 5, 2023. <pub-id pub-id-type="doi">10.6084/m9.figshare.24712464</pub-id></mixed-citation>
      </ref>
      <ref id="dgae210-B39">
        <label>39</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kleinendorst</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Abawi</surname><given-names>O</given-names></string-name>, <string-name><surname>van der Voorn</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Identifying underlying medical causes of pediatric obesity: results of a systematic diagnostic approach in a pediatric obesity center</article-title>. <source>PLoS One</source>. <year>2020</year>;<volume>15</volume>(<issue>5</issue>):<fpage>e0232990</fpage>.<pub-id pub-id-type="pmid">32384097</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B40">
        <label>40</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Richards</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Aziz</surname><given-names>N</given-names></string-name>, <string-name><surname>Bale</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology</article-title>. <source>Genet Med</source>. <year>2015</year>;<volume>17</volume>(<issue>5</issue>):<fpage>405</fpage>&#x2010;<lpage>424</lpage>.<pub-id pub-id-type="pmid">25741868</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B41">
        <label>41</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chima</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Mulrooney</surname><given-names>HM</given-names></string-name>, <string-name><surname>Warren</surname><given-names>J</given-names></string-name>, <string-name><surname>Madden</surname><given-names>AM</given-names></string-name></person-group>. <article-title>A systematic review and quantitative analysis of resting energy expenditure prediction equations in healthy overweight and obese children and adolescents</article-title>. <source>J Hum Nutr Diet</source>. <year>2020</year>;<volume>33</volume>(<issue>3</issue>):<fpage>373</fpage>&#x2010;<lpage>385</lpage>.<pub-id pub-id-type="pmid">32073189</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B42">
        <label>42</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schofield</surname>
<given-names>WN</given-names>
</string-name>
</person-group>. <article-title>Predicting basal metabolic rate, new standards and review of previous work</article-title>. <source>Hum Nutr Clin Nutr</source>. <year>1985</year>;<volume>39</volume>(<issue>Suppl 1</issue>):<fpage>5</fpage>&#x2010;<lpage>41</lpage>.<pub-id pub-id-type="pmid">4044297</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B43">
        <label>43</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Roza</surname>
<given-names>AM</given-names>
</string-name>, <string-name><surname>Shizgal</surname><given-names>HM</given-names></string-name></person-group>. <article-title>The Harris Benedict equation reevaluated: resting energy requirements and the body cell mass</article-title>. <source>Am J Clin Nutr</source>. <year>1984</year>;<volume>40</volume>(<issue>1</issue>):<fpage>168</fpage>&#x2010;<lpage>182</lpage>.<pub-id pub-id-type="pmid">6741850</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B44">
        <label>44</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kruizenga</surname>
<given-names>HM</given-names>
</string-name>, <string-name><surname>Hofsteenge</surname><given-names>GH</given-names></string-name>, <string-name><surname>Weijs</surname><given-names>PJ</given-names></string-name></person-group>. <article-title>Predicting resting energy expenditure in underweight, normal weight, overweight, and obese adult hospital patients</article-title>. <source>Nutr Metab (Lond)</source>. <year>2016</year>;<volume>13</volume>(<issue>1</issue>):<fpage>85</fpage>.<pub-id pub-id-type="pmid">27904645</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B45">
        <label>45</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lohman</surname>
<given-names>T</given-names>
</string-name>
</person-group>. <article-title>Assessment of body composition in children</article-title>. <source>Pediatr Exerc Sci</source>. <year>1989</year>;<volume>1</volume>(<issue>1</issue>):<fpage>19</fpage>&#x2010;<lpage>30</lpage>.<pub-id pub-id-type="pmid">36696627</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B46">
        <label>46</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hammad</surname>
<given-names>MM</given-names>
</string-name>, <string-name><surname>Mohammad</surname><given-names>A</given-names></string-name>, <string-name><surname>Alam-Eldin</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor</article-title>. <source>Life Sci</source>. <year>2022</year>;<volume>307</volume>:<fpage>120857</fpage>.<pub-id pub-id-type="pmid">35931197</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B47">
        <label>47</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hinney</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Schmidt</surname><given-names>A</given-names></string-name>, <string-name><surname>Nottebom</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans</article-title>. <source>J Clin Endocr Metab</source>. <year>1999</year>;<volume>84</volume>(<issue>4</issue>):<fpage>1483</fpage>&#x2010;<lpage>1486</lpage>.<pub-id pub-id-type="pmid">10199800</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B48">
        <label>48</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<collab>EU/3/18/2101</collab>
</person-group>. <source>Orphan Designation for the Treatment of Leptin Receptor Deficiency</source>. <publisher-name>European Medicines Agency</publisher-name>; <year>2018</year>.</mixed-citation>
      </ref>
      <ref id="dgae210-B49">
        <label>49</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<collab>FDA</collab>
</person-group>. <source>FDA approves First Treatment for Weight Management for People with Certain Rare Genetic Conditions</source>. <publisher-name>U.S. Food &amp; Drug Administration</publisher-name>; <year>2020</year>.</mixed-citation>
      </ref>
      <ref id="dgae210-B50">
        <label>50</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Reininghaus</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Paisdzior</surname><given-names>S</given-names></string-name>, <string-name><surname>Hopfner</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>A setmelanotide-like effect at MC4R is achieved by MC4R dimer separation</article-title>. <source>Biomolecules</source>. <year>2022</year>;<volume>12</volume>(<issue>8</issue>):<fpage>1119</fpage>.<pub-id pub-id-type="pmid">36009013</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B51">
        <label>51</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Paisdzior</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Dimitriou</surname><given-names>IM</given-names></string-name>, <string-name><surname>Schope</surname><given-names>PC</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Differential signaling profiles of MC4R mutations with three different ligands</article-title>. <source>Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>(<issue>4</issue>):<fpage>1224</fpage>.<pub-id pub-id-type="pmid">32059383</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B52">
        <label>52</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dunham</surname>
<given-names>JH</given-names>
</string-name>, <string-name><surname>Hall</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Enhancement of the surface expression of G protein-coupled receptors</article-title>. <source>Trends Biotechnol</source>. <year>2009</year>;<volume>27</volume>(<issue>9</issue>):<fpage>541</fpage>&#x2010;<lpage>545</lpage>.<pub-id pub-id-type="pmid">19679364</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B53">
        <label>53</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ulloa-Aguirre</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Zarinan</surname><given-names>T</given-names></string-name>, <string-name><surname>Dias</surname><given-names>JA</given-names></string-name>, <string-name><surname>Conn</surname><given-names>PM</given-names></string-name></person-group>. <article-title>Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function</article-title>. <source>Mol Cell Endocrinol</source>. <year>2014</year>;<volume>382</volume>(<issue>1</issue>):<fpage>411</fpage>&#x2010;<lpage>423</lpage>.<pub-id pub-id-type="pmid">23806559</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B54">
        <label>54</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gray</surname>
<given-names>DL</given-names>
</string-name>, <string-name><surname>Allen</surname><given-names>JA</given-names></string-name>, <string-name><surname>Mente</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Impaired beta-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor</article-title>. <source>Nat Commun</source>. <year>2018</year>;<volume>9</volume>(<issue>1</issue>):<fpage>674</fpage>.<pub-id pub-id-type="pmid">29445200</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B55">
        <label>55</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tao</surname>
<given-names>YX</given-names>
</string-name>, <string-name><surname>Segaloff</surname><given-names>DL</given-names></string-name></person-group>. <article-title>Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2005</year>;<volume>90</volume>(<issue>10</issue>):<fpage>5632</fpage>&#x2010;<lpage>5638</lpage>.<pub-id pub-id-type="pmid">16030156</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B56">
        <label>56</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tao</surname>
<given-names>YX</given-names>
</string-name>
</person-group>. <article-title>Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity</article-title>. <source>Mol Cell Endocrinol</source>. <year>2005</year>;<volume>239</volume>(<issue>1-2</issue>):<fpage>1</fpage>&#x2010;<lpage>14</lpage>.<pub-id pub-id-type="pmid">15975705</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B57">
        <label>57</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tao</surname>
<given-names>YX</given-names>
</string-name>, <string-name><surname>Segaloff</surname><given-names>DL</given-names></string-name></person-group>. <article-title>Functional characterization of melanocortin-4 receptor mutations associated with childhood obesity</article-title>. <source>Endocrinology</source>. <year>2003</year>;<volume>144</volume>(<issue>10</issue>):<fpage>4544</fpage>&#x2010;<lpage>4551</lpage>.<pub-id pub-id-type="pmid">12959994</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B58">
        <label>58</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Huang</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Tao</surname><given-names>YX</given-names></string-name></person-group>. <article-title>Pleiotropic functions of the transmembrane domain 6 of human melanocortin-4 receptor</article-title>. <source>J Mol Endocrinol</source>. <year>2012</year>;<volume>49</volume>(<issue>3</issue>):<fpage>237</fpage>&#x2010;<lpage>248</lpage>.<pub-id pub-id-type="pmid">23014839</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B59">
        <label>59</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chai</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Li</surname><given-names>JY</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name><surname>Newman</surname><given-names>E</given-names></string-name>, <string-name><surname>Ammori</surname><given-names>J</given-names></string-name>, <string-name><surname>Mulholland</surname><given-names>MW</given-names></string-name></person-group>. <article-title>Melanocortin-4 receptor-mediated inhibition of apoptosis in immortalized hypothalamic neurons via mitogen-activated protein kinase</article-title>. <source>Peptides</source>. <year>2006</year>;<volume>27</volume>(<issue>11</issue>):<fpage>2846</fpage>&#x2010;<lpage>2857</lpage>.<pub-id pub-id-type="pmid">16806584</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B60">
        <label>60</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Daniels</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Patten</surname><given-names>CS</given-names></string-name>, <string-name><surname>Roth</surname><given-names>JD</given-names></string-name>, <string-name><surname>Yee</surname><given-names>DK</given-names></string-name>, <string-name><surname>Fluharty</surname><given-names>SJ</given-names></string-name></person-group>. <article-title>Melanocortin receptor signaling kinase in vitro and through mitogen-activated protein in rat hypothalamus</article-title>. <source>Brain Res</source>. <year>2003</year>;<volume>986</volume>(<issue>1-2</issue>):<fpage>1</fpage>&#x2010;<lpage>11</lpage>.<pub-id pub-id-type="pmid">12965224</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B61">
        <label>61</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>He</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Tao</surname><given-names>YX</given-names></string-name></person-group>. <article-title>Defect in MAPK signaling as a cause for monogenic obesity caused by inactivating mutations in the melanocortin-4 receptor gene</article-title>. <source>Int J Biol Sci</source>. <year>2014</year>;<volume>10</volume>(<issue>10</issue>):<fpage>1128</fpage>&#x2010;<lpage>1137</lpage>.<pub-id pub-id-type="pmid">25332687</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B62">
        <label>62</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wei</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Ahn</surname><given-names>S</given-names></string-name>, <string-name><surname>Shenoy</surname><given-names>SK</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2003</year>;<volume>100</volume>(<issue>19</issue>):<fpage>10782</fpage>&#x2010;<lpage>10787</lpage>.<pub-id pub-id-type="pmid">12949261</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B63">
        <label>63</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Smith</surname>
<given-names>JS</given-names>
</string-name>, <string-name><surname>Pack</surname><given-names>TF</given-names></string-name></person-group>. <article-title>Noncanonical interactions of G proteins and beta-arrestins: from competitors to companions</article-title>. <source>FEBS J</source>. <year>2021</year>;<volume>288</volume>(<issue>8</issue>):<fpage>2550</fpage>&#x2010;<lpage>2561</lpage>.<pub-id pub-id-type="pmid">33539669</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B64">
        <label>64</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mo</surname>
<given-names>XL</given-names>
</string-name>, <string-name><surname>Tao</surname><given-names>YX</given-names></string-name></person-group>. <article-title>Activation of MAPK by inverse agonists in six naturally occurring constitutively active mutant human melanocortin-4 receptors</article-title>. <source>Biochim Biophys Acta</source>. <year>2013</year>;<volume>1832</volume>(<issue>12</issue>):<fpage>1939</fpage>&#x2010;<lpage>1948</lpage>.<pub-id pub-id-type="pmid">23791567</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B65">
        <label>65</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Botha</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Kumar</surname><given-names>SS</given-names></string-name>, <string-name><surname>Grimsey</surname><given-names>NL</given-names></string-name>, <string-name><surname>Mountjoy</surname><given-names>KG</given-names></string-name></person-group>. <article-title>A unique melanocortin-4-receptor signaling profile for obesity-associated constitutively active variants</article-title>. <source>J Mol Endocrinol</source>. <year>2023</year>;<volume>71</volume>(<issue>1</issue>):<fpage>e230008</fpage>.<pub-id pub-id-type="pmid">37040537</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B66">
        <label>66</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mousseaux</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Le Gallic</surname><given-names>L</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Regulation of ERK1/2 activity by ghrelin-activated growth hormone secretagogue receptor 1A involves a PLC/PKCvarepsilon pathway</article-title>. <source>Br J Pharmacol</source>. <year>2006</year>;<volume>148</volume>(<issue>3</issue>):<fpage>350</fpage>&#x2010;<lpage>365</lpage>.<pub-id pub-id-type="pmid">16582936</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B67">
        <label>67</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Leroy</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Missotten</surname><given-names>M</given-names></string-name>, <string-name><surname>Waltzinger</surname><given-names>C</given-names></string-name>, <string-name><surname>Martin</surname><given-names>T</given-names></string-name>, <string-name><surname>Scheer</surname><given-names>A</given-names></string-name></person-group>. <article-title>G protein-coupled receptor-mediated ERK1/2 phosphorylation: towards a generic sensor of GPCR activation</article-title>. <source>J Recept Signal Transduct Res</source>. <year>2007</year>;<volume>27</volume>(<issue>1</issue>):<fpage>83</fpage>&#x2010;<lpage>97</lpage>.<pub-id pub-id-type="pmid">17365511</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B68">
        <label>68</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kumar</surname>
<given-names>SS</given-names>
</string-name>, <string-name><surname>Ward</surname><given-names>ML</given-names></string-name>, <string-name><surname>Mountjoy</surname><given-names>KG</given-names></string-name></person-group>. <article-title>Quantitative high-throughput assay to measure MC4R-induced intracellular calcium</article-title>. <source>J Mol Endocrinol</source>. <year>2021</year>;<volume>66</volume>(<issue>4</issue>):<fpage>285</fpage>&#x2010;<lpage>297</lpage>.<pub-id pub-id-type="pmid">33739935</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B69">
        <label>69</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kleinau</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Muller</surname><given-names>A</given-names></string-name>, <string-name><surname>Biebermann</surname><given-names>H</given-names></string-name></person-group>. <article-title>Oligomerization of GPCRs involved in endocrine regulation</article-title>. <source>J Mol Endocrinol</source>. <year>2016</year>;<volume>57</volume>(<issue>1</issue>):<fpage>R59</fpage>&#x2010;<lpage>R80</lpage>.<pub-id pub-id-type="pmid">27151573</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B70">
        <label>70</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chan</surname>
<given-names>LF</given-names>
</string-name>, <string-name><surname>Webb</surname><given-names>TR</given-names></string-name>, <string-name><surname>Chung</surname><given-names>TT</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>MRAP and MRAP2 are bidirectional regulators of the melanocortin receptor family</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2009</year>;<volume>106</volume>(<issue>15</issue>):<fpage>6146</fpage>&#x2010;<lpage>6151</lpage>.<pub-id pub-id-type="pmid">19329486</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B71">
        <label>71</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kirchberg</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Kim</surname><given-names>TY</given-names></string-name>, <string-name><surname>Moller</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Conformational dynamics of helix 8 in the GPCR rhodopsin controls arrestin activation in the desensitization process</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2011</year>;<volume>108</volume>(<issue>46</issue>):<fpage>18690</fpage>&#x2010;<lpage>18695</lpage>.<pub-id pub-id-type="pmid">22039220</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B72">
        <label>72</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Seyedabadi</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Gharghabi</surname><given-names>M</given-names></string-name>, <string-name><surname>Gurevich</surname><given-names>EV</given-names></string-name>, <string-name><surname>Gurevich</surname><given-names>VV</given-names></string-name></person-group>. <article-title>Receptor-Arrestin interactions: the GPCR perspective</article-title>. <source>Biomolecules</source>. <year>2021</year>;<volume>11</volume>(<issue>2</issue>):<fpage>218</fpage>.<pub-id pub-id-type="pmid">33557162</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B73">
        <label>73</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Moore</surname>
<given-names>BS</given-names>
</string-name>, <string-name><surname>Mirshahi</surname><given-names>T</given-names></string-name></person-group>. <article-title>Genetic variants help define the role of the MC4R C-terminus in signaling and cell surface stability</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>10397</fpage>.<pub-id pub-id-type="pmid">29991773</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B74">
        <label>74</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Calton</surname>
<given-names>MA</given-names>
</string-name>, <string-name><surname>Ersoy</surname><given-names>BA</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Association of functionally significant Melanocortin-4 but not Melanocortin-3 receptor mutations with severe adult obesity in a large north American case-control study</article-title>. <source>Hum Mol Genet</source>. <year>2009</year>;<volume>18</volume>(<issue>6</issue>):<fpage>1140</fpage>&#x2010;<lpage>1147</lpage>.<pub-id pub-id-type="pmid">19091795</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B75">
        <label>75</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Buchbinder</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Bartsch</surname><given-names>U</given-names></string-name>, <string-name><surname>Muller</surname><given-names>M</given-names></string-name>, <string-name><surname>Zorn</surname><given-names>M</given-names></string-name>, <string-name><surname>Nawroth</surname><given-names>PP</given-names></string-name>, <string-name><surname>Schilling</surname><given-names>T</given-names></string-name></person-group>. <article-title>A novel missense mutation T101N in the melanocortin-4 receptor gene associated with obesity</article-title>. <source>Genet Mol Res</source>. <year>2011</year>;<volume>10</volume>(<issue>2</issue>):<fpage>1042</fpage>&#x2010;<lpage>1049</lpage>.<pub-id pub-id-type="pmid">21710454</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B76">
        <label>76</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chami</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Preuss</surname><given-names>M</given-names></string-name>, <string-name><surname>Walker</surname><given-names>RW</given-names></string-name>, <string-name><surname>Moscati</surname><given-names>A</given-names></string-name>, <string-name><surname>Loos</surname><given-names>RJF</given-names></string-name></person-group>. <article-title>The role of polygenic susceptibility to obesity among carriers of pathogenic mutations in MC4R in the UK biobank population</article-title>. <source>PLoS Med</source>. <year>2020</year>;<volume>17</volume>(<issue>7</issue>):<fpage>e1003196</fpage>.<pub-id pub-id-type="pmid">32692746</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B77">
        <label>77</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Clement</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>van den Akker</surname><given-names>E</given-names></string-name>, <string-name><surname>Argente</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2020</year>;<volume>8</volume>(<issue>12</issue>):<fpage>960</fpage>&#x2010;<lpage>970</lpage>.<pub-id pub-id-type="pmid">33137293</pub-id>
</mixed-citation>
      </ref>
      <ref id="dgae210-B78">
        <label>78</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>HB</given-names>
</string-name>, <string-name><surname>Chen</surname><given-names>LN</given-names></string-name>, <string-name><surname>Yang</surname><given-names>DH</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Structural insights into ligand recognition and activation of the melanocortin-4 receptor</article-title>. <source>Cell Res</source>. <year>2021</year>;<volume>31</volume>(<issue>11</issue>):<fpage>1163</fpage>&#x2010;<lpage>1175</lpage>.<pub-id pub-id-type="pmid">34433901</pub-id>
</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>